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Static parameters of maternal cardiovascular function have been studied well using a variety of 
methods. However, studies on dynamic assessment of maternal cardiovascular function are 
scarce.  Gestational age related serial changes in maternal preload reserve have not been studied, 
and there is a need to establish normal reference intervals for functional hemodynamic 
parameters during pregnancy. Furthermore, how functional hemodynamics may be affected in 
high-risk pregnancies and whether it could be used to predict pregnancy complications has not 
been properly explored. 
Objectives 
The aim of this thesis was to investigate maternal functional hemodynamics in normal 
pregnancies and in pregnancies at risk of developing placental dysfunction disorders. 
The main objectives were: 
A. To investigate functional hemodynamic response to passive leg raising (PLR) in healthy 
pregnant women at 22-24 weeks of gestation and compare with non-pregnant women. 
B. To investigate cardiovascular response to PLR in healthy pregnant women and establish 
longitudinal reference ranges for the second half of pregnancy. 
C. To compare cardiac function, systemic hemodynamics and preload reserve among 
women with increased and normal uterine artery pulsatility index (UtA PI) at 22-24 
weeks of gestation. 
Methods 
Systemic hemodynamics and cardiac function were evaluated during rest and after PLR to 
assess cardiovascular response to a change in preload using noninvasive impedance 
cardiography (ICG). Utero-placental circulation in pregnant women was evaluated using 
Doppler ultrasonography. 
In a prospective cross-sectional study, 108 low-risk pregnant women (22-24 weeks of gestation) 
and 54 non-pregnant women (in the follicular phase of menstrual cycle) were examined to 
investigate differences in functional hemodynamics in response to PLR. 
In a longitudinal study, cardiovascular function was serially assessed at baseline and after PLR 
at approximately 4-weekly intervals in 98 healthy pregnant women during 20-41 weeks of 
gestation to establish normal reference ranges for maternal functional hemodynamics. 
In another prospective cross-sectional study, functional hemodynamics and utero-placental 
circulation were assessed in 620 unselected pregnant women during 22-24 gestational weeks to 
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investigate whether pregnant women at increased risk of developing placental dysfunction 
disorders as identified by abnormal UtA PI have a different functional hemodynamic profile 
compared to low-risk women. 
Results 
PLR caused significant changes in the majority of hemodynamic variables both in pregnant (at 
22-24 weeks of gestation) and non-pregnant women. The hemodynamic response to PLR was 
similar in both groups with similar trend and magnitude of change (∆ %). Approximately, 15% 
of pregnant women and 11% of non-pregnant women increased their stroke volume (SV) above 
10% after 90s of PLR. For the cardiac output (CO) the proportion was 13% and 18.5%, 
respectively. 
The effect of modified preload caused by PLR on cardiac function and hemodynamics varied 
by gestation, and varied among individual pregnant women at different gestations. There was 
no significant association between the gestational age and % change in SV and heart rate (HR) 
from baseline to PLR. During PLR there was an increase in SV from 20+0 to 31+6 weeks of 
gestation, but later in gestation the SV was slightly decreased by PLR. The CO decreased after 
24 weeks in response to PLR. The HR, blood pressure and cardiac contractility decreased by 
PLR throughout the second half of pregnancy. In response to PLR, the systemic vascular 
resistance (SVR) was reduced until 32 weeks, and then it slightly increased until term. 
The mean arterial pressure (MAP) and SVR were significantly higher at baseline among 
pregnant women with high mean UtA PI compared to controls. 28.6% of women with high UtA 
PI developed pregnancy complications compared to 9.5% in the control group. However, the 
functional hemodynamic response to PLR was not different between groups. The SV increased 
significantly (4-5%) following PLR in both groups. whereas cardiac output remained 
unchanged. 
Conclusions 
Maternal hemodynamics is different in healthy pregnant women compared to non-pregnant 
women. In healthy pregnancies, the physiological response to PLR was not modified at 22-24 
weeks of gestation. 
Longitudinal reference ranges for maternal functional hemodynamics were established for the 
second half of pregnancy. Healthy pregnant women appear to have limited preload reserve, 
especially in the third trimester, and might be vulnerable to fluid overload and cardiac failure. 
The functional hemodynamic profile of pregnant women with high UtA PI at 22-24 weeks 
was similar to that of controls, suggesting that its assessment is unlikely to improve the value 
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Measurements of heart rate (HR), stroke volume (SV), cardiac output (CO), mean arterial 
pressure (MAP), central venous pressure (CVP) and systemic vascular resistance (SVR) are 
generally used to assess maternal systemic hemodynamics. Non-invasive methods, such as 
Doppler echocardiography, impedance cardiography (ICG) and cardiac magnetic resonance 
imaging (cMRI) are often used to evaluate cardiovascular function, and have in many clinical 
situations replaced the more invasive methods that require cardiac catheterization. With the 
development and validation of noninvasive techniques it has become easier to perform repeated 
measurements and longitudinal studies during pregnancy. Methods that allow continuous 
measurement and monitoring of cardiovascular function over a time period are more useful in 
clinical settings. Although static measures of cardiovascular function are reasonably well 
studied during pregnancy, dynamic assessment of cardiovascular function has rarely been 
performed to assess physiological changes that occur with advancing gestation and to evaluate 
the role of functional hemodynamics in the prediction, diagnosis and management of 
pregnancy complications. 
2 CARDIOVASCULAR PHYSIOLOGY 
The cardiovascular system, which consists of the heart and the blood vessels, transports oxygen 
and nutrients to cells and tissues of the body, and removes carbon dioxide and waste products. 
The cardiac function is the ability of the heart to pump blood into the aorta and the pulmonary 
arteries resulting in adequate tissue perfusion required to meet metabolic demands of different 
organs. The cardiac cycle consists of two phases: diastole, when the ventricles relax and are 
filled with blood, and systole when the ventricles contract and pump blood into the systemic 
and pulmonary circulation. The total cardiac cycle can be divided into four different 
phases/periods: isovolumic ventricular relaxation and ventricular filling (rapid filling, slow 
filling and atrial contraction) constituting the diastole, and isovolumic ventricular contraction 
and ejection constituting the systole. The cardiac cycle is generally assumed to start with atrial 
contraction (P-wave on electrocardiogram) and end when the slow filling of the ventricle ends. 
Dynamic changes in myocardial motion (deformation) and ventricular pressure occur during 
the cardiac cycle. Changes in ventricular volume occur except during the isovolumic phases. 
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2.1 Factors affecting cardiac function 
Cardiac function can be described by the ventricular pressure-volume changes that occur during 
the cardiac cycle and the time intervals of different phases/periods of the cardiac cycle. Cardiac 
function is affected by several intrinsic and extrinsic factors. The SV is the difference between 
the ventricular end-systolic volume (ESV) and the end-diastolic volume (EDV). The ejection 
fraction (EF), calculated as: EF=SV/EDV x 100 %, is a widely used parameter describing 
systolic function of the heart. CO is the product of SV and HR. SVR is calculated as: MAP-
CVP/CO. 
Myocardial Contractility 
The heart consists of cardiac muscle fibers made up of two types of cardiac muscle cells, 
cardiomyocytes and cardiac pacemaker cells. The atria and ventricles consist of about 99% of 
cardiomyocyte cells, and each cell contains specialized myofibrils (sarcomeres), which are the 
contractile units of the muscle cells. These cells have the intrinsic ability to shorten and to 
lengthen the muscle fibers. The cardiac muscle contracts as a response to impulses (action 
potential) from the pacemaker cells (1%), which constitute the conducting system distributed 
throughout the heart. 
Sympathetic and parasympathetic nerve fibers innervate the cardiac muscle cells (and the 
conducting system) coordinating contraction and relaxation of the cardiac muscle tissue to 
obtain an efficient pumping action of the heart. However, heart can pump efficiently even 
without any nerve supply or cardiac pacing (such as following cardiac transplantation) 
maintaining the CO and balance between systemic and pulmonary circulation. 
Sympathetic stimulation by norepinephrine and epinephrine stimulates the cardiac muscle to 
contract faster and stronger. Sympathetic stimulation over a longer time period can cause 
cardiac hypertrophy, an increase of the ventricles wall thickness. There are two types of cardiac 
hypertrophy, eccentric and concentric hypertrophy. Eccentric hypertrophy results from e.g. 
aerobic training and pregnancy, and is caused by an increase of blood volume returning to the 
heart (volume overload) resulting in new sarcomeres in series by lengthening rather than 
thickening of the muscle. The ability of the heart to expand by receiving greater volume of 
blood enables the ventricle to generate greater forces. Concentric hypertrophy results from 
disease as a response to pressure overload, such as chronic hypertension. This results in an 




2.2 Preload  
Preload is described as the wall stress of the ventricle by initial stretching of the cardiac 
myocytes just prior to contraction depending on the amount of blood returning into the ventricle 
[1]. Preload determines end-diastolic sarcomere length and therefore, the force of contraction. 
In an intact heart the length of sarcomeres, myofibrils, cannot be measured. However, the end-
diastolic pressure (EDP) and the EDV are related to the degree of stretching of the myocytes, 
and can be used to describe preload. 
The venous blood pressure, the circulating blood volume and the rate of venous return affect 
preload. The two main body “pumps” affect venous return: 
1. The respiratory pump, where the intra-thoracic pressure is decreased during inspiration with 
an increase in the abdominal pressure followed by squeezing of the abdominal veins and 
increase of blood flow towards the right atrium. 
2. The skeletal muscle pump, where the surrounding muscles squeeze the veins and pump blood 
back towards the heart. 
Changes in venous compliance affect preload. Increased venous compliance (e.g. during spinal 
anesthesia) reduces preload, and a decrease in venous compliance (e.g. due to hemorrhage 
leading to vasoconstriction) results in an improved venous return and an increase in preload. 
The EDP of the left ventricle correlates with left atrial pressure, which can be indirectly 
measured as pulmonary capillary wedge pressure (PCWP) using pulmonary artery 
catheterization (Swan-Ganz catheter). 
The EDV is another surrogate for preload. The main factor determining the EDV is the 
ventricular filling time. The faster the heart rate, the shorter is the filling time, leading to a 
reduced EDV. Sympathetic stimulation of the venous system increases the venous return to the 
heart and the ventricular filling. An opposite response occurs by parasympathetic stimulation. 
The ventricular wall stress can be expressed based on Laplace’s law as: Wall stress = (pressure 
x radius)/2 x wall thickness. Preload can be calculated using echocardiography as: (LVEDV x 
LVEDR)/2h, where LVEDV is left ventricle end diastolic volume. LVEDR is left ventricle end 
diastolic radius (at the ventricle’s midpoint) and h is thickness of the ventricle. 
2.3 Afterload 
Afterload is the load the ventricular myocardium faces during active force development, and it 
determines the degree of myocardial fiber shortening. In order to open the aortic and pulmonary 
valves, the pressure in the left and the right ventricle must be greater than the systemic and the 
pulmonary pressures, respectively. The SVR reflects the afterload of the cardiovascular system 
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and it is the main determinant of myocardial oxygen consumption. SVR represents the force or 
pressure the ventricle must overcome to eject blood into the aorta [2]. The pressure is assessed 
by measurement of the gradient between the beginning of the circuit (MAP) and the end (CVP). 
This value is then divided by the volume of blood flow i.e. CO. SVR = 1333.22 x (MAP-
CVP)/CO. A conversion factor of 1333.22 is used to adjust the value into the units of force for 
SVR as dyne.s.cm-5 (1 mmHg = 1333.22 dynes.cm-2 and ml = cm3). This can be simplified to: 
SVR, dyne.s.cm-5 = 80 (MAP, mmHg – CVP, mmHg)/CO, l/min. Some researchers have 
reported SVR as total peripheral vascular resistance (PVR or TVR) calculated as 
80x(MAP/CO) mmHg/ml disregarding the CVP which is normally quite low [3] [4]. Normal 
SVR is 800-1200 dynes.s.cm-5. An increase in afterload caused by, e.g. systemic hypertension 
or aortic valve disease, is followed by a decreased SV and CO. 
 
Frank-Starling mechanism 
The Frank-Starling mechanism was established from studies performed by Otto Frank and 
Ernest Starling in the late 19th and early 20th century. Frank observed that the strength of the 
ventricular contraction increased when the ventricle was stretched. Starling found that increased 
venous return to the heart and increased left ventricular EDP (LVEDP) resulted in an increase 
of SV.   
The Frank-Starling mechanism (also called Starling’s law of the heart) refers to the ability of 
the heart to change its contractility and stroke volume in response to changes in venous return 
and ventricular filling pressure. The force of ventricular contraction is directly proportional to 
the initial length of muscle fiber. During exercise increased volume of blood returns to the heart 
that causes an increase of venous return and end-diastolic volume resulting in stretching of the 
heart muscle. Thus, the more the ventricular muscle is stretched the more forceful is the 
ventricular contraction (within certain limits). The distension of the ventricle leads to greater 
ejection pressure and increased ventricular contractility, which will increase the SV and the CO 
due to increased preload (end-diastolic volume). An opposite effect occurs with a reduction in 
the velocity of fiber shortening and the velocity of ejection of blood resulting in reduced CO 
and SV [1].  
2.4 Vascular physiology 
The vascular system includes the systemic and the pulmonary circulation. In the adults under 
physiological conditions there is a balance between systemic and pulmonary circulations, i.e. 
pulmonary blood flow (Qp) = systemic blood flow (Qs). The blood volume and blood pressure 
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are the main determinants of end-diastolic volume (EDV), SV and CO. Approximately 70% of 
the total blood of the systemic circulation is stored in the venous system [5] and serves as a 
reservoir of blood. Veins are more compliant compared to arteries having the ability to 
accommodate changes in blood volume by being more distensible. Venous compliance is 
defined as; ∆V / ∆P, where ∆V is the change in volume of blood within a vein (or venous 
system) and ∆P is the change of intravenous distending pressure [5]. 
2.5 Factors affecting blood flow 
Blood flows from high pressure to low-pressure regions. Blood flow (Q) = Pressure 
(P)/Resistance (R). Vascular resistance is determined by two factors; a) blood viscosity (ŋ) and 
b) blood vessel size [the length (L) and radius (r)], and it can be determined using the following 
formula: R= (ŋ L/r4) x (8/π) or R = 8Lη/πr4. According to Poiseuille’s law Q = πr4 (P1-P2)/8Lη. 
Blood viscosity increases with increasing hematocrit of the blood. This can have an important 
effect on the resistance to flow in certain conditions. The most important determinant of 
changes in resistance is the radius of the blood vessel. If the radius increases two-fold, the 
resistance decreases sixteen-fold, resulting in sixteen-fold increase of flow at a constant 
pressure. 
The major sites of resistance to flow are the arterioles participating in the regulation of arterial 
blood pressure. In low-resistance vessels, blood flows to organs with little loss in pressure. They 
act as pressure reservoir for maintaining blood flow during ventricular relaxation. 
3 CARDIOVASCULAR ADAPTATION TO PREGNANCY 
Pregnancy causes significant changes in the cardiovascular system by alteration in maternal 
cardiac function and hemodynamics [2, 6-9]. A century ago Lindhard showed that pregnant 
women have higher cardiac output (CO) than non-pregnant women [10]. Since then several 
studies on maternal hemodynamics have been performed using invasive and non-invasive 
methods (Tables 1, 2 and 3). Many of these studies have shown variable results depending on 
their study design, methodology and the position of the participant during examination [6]. 
14 























1 L Fick Sitting 23-40 5.2-5.5     Lindhard (1915) [10] 
68 C Fick Not described 6-40 4.29-4.60     Hamilton (1949) [11] 
84 C Fick Not described 12-40 6.2-5.7     Palmer (1949) [12] 
46 C Fick Not described 14-40 6.53-5.53 986-1244  70-58 99-96 Bader (1955) [13] 
46 C Fick Not described 14-40 6.53-5.53 986-1244  70-58 99-96 Rose (1956) [14] 
30 L Dye  Not described 8-43 7.01-6.19   91-79 77.55-78.86 Walters (1966) [15] 
5 L Fick Lateral  11-37 6.10-6.26  81.6-86.2 75.6-75.8 81.4-84.2 Lees (1967) [16] 
11 L Dye Left lateral  20-40 6.9-5.7   94.5-69.0 73.4-83.2  Ueland (1969) [17] 
10 C Dye  Left lateral 36-39    95.5 78.2 Milsom (1983) [18] 
10 C TD Left lateral 36-38 6.2 1210 90.3  83 Clark (1989) [19] 
20 L Fick Sitting  8-40 3.8-4.6#   50 - 50 83-87# Spätling (1992)# [20] 
Dye, dye dilution and TD, thermodilution. C, cross sectional and L, longitudinal. CO, cardiac output; SVR, systemic vascular resistance; MAP, mean arterial pressure; 
SV, stroke volume and HR, heart rate. Hemodynamic parameters from cross sectional studies presented as mean values. #Spätling: value estimated from figure (box 













































Rubler (1977) [21] 
19 L Left lateral 12-38 5.71-8.56  68-66 75-97 77-88 Katz (1978) [22] 
18 C Semi-recumbent 3.Tr 6.6 996 76.8 81.5 82.7 Easterling (1987) [23] 



















Easterling (1988) [24]  
8 L Left lateral 8-24 5.2-5.7 969-930 62-67 79-81 68-73 Capeless (1989) [25] 
13 L Left semi-lateral 5-38 5.40-7.22 1213-966 80.3-86 68.6-83.6 79-87 Robson (1989) [26] 
20 L Left lateral  15-35 6.13-7.25 1328-1151 97-100 77.3-83.0 74-82 Bolter (1990) [27] 
16 C Supine 24-36 8.41 821 76.71 95.79 83.8 Droste (1992) [28] 
10 L Semi-left lateral 5-35 5.24-5.78 1252-1257  90-91 74-68 76-85 Duvekot (1993) [29] 
40 L Left lateral 20-38 6.48-7.54     Thomsen (1993) [30] 
18 L Left lateral  8-39 6.7-8.5 1008-829 84-88 85-98 80-88 Mabie (1994) [31] 
26 L Left lateral 24-40 5.0-5.7 1360-1302 83-91 60-71 86-82 Hennessy (1996) [32] 
30 L Left-lateral  8-38 5.90-6.91 1080-946 80-82 92-96 64-72 Clapp (1997) [33] 
34 L Left lateral  10-38 5.8-7.35 1076.1-818.2 75.6-78.0 82.4-96.6 71.6-78.3 Geva (1997) [34] 
76 L Left lateral  15-36 5.0-5.8 1027-941 59-62 66-70 75-82 Gilson (1997) [35] 
14 L Left lateral 12-31 6.8-7.9 885-743 71-70 95-99 70-80 Poppas (1997) [36] 
37 L Left lateral 10-34 4.6-6.0 1485-1143 83-82 62-71 74-87 Mesa (1999) [37] 
43 L Semi-recumbent 12-33 5.6-6.6 1188-1023  79.6-79.9 67-77  Valensise (2000) [38] 
13 L Left lateral  10-34 6.75-6.85 1037-912   81.5-75.9 81.9-78.6  81.6-87.2   Del Bene (2001)# [39] 
46 L Not described 9-33 4.5-6.7 1386-895 85.1-82.6 64-76 71-89 Schannwell (2002) [40] 
35 L Left lateral 14-37 4.96-6.94 1214-902 74-74 66-87 75-79 Desai (2004) [41] 
41 C Lateral 28-31 6.75 949 78 77 87 Valensise (2006) [42] 
104 C Left lateral 11-38 6.34 995.39 76.47 79.60 79.87 Bamfo (2007) [43]   
26 C Left lateral 20-36  6.1 1088 79.5 73.6 84.3 Bamfo (2007) [44]  
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17 C Left lateral 33-38 7.31 932.63 82.09 89.78 82.64 Bamfo (2007) [45] 















Turan (2008)§& [47] 
1119 C Lateral  24 6.61 990 80 83 80 Valensise (2008) [48] 
429 C Lateral 24 6.57 1009 80 82 80 Vasapollo (2008) [49] 
17 C Left lateral 13-40 5.8-6.7 2062-1858 78-80 80-88 73-77 Abdullah (2012) [50] 
26 C Left lateral ≥ 32 5.8 993  74  Burlingame (2013) 
[51] 
63 L Left lateral  14-36 5.7-6.0 15-14.5  82.8-84.8 78-75 73-80 Estensen (2013) [52] 
105 C Left lateral 20-23 5.6 1067 80 72 81 Melchiorre (2013) [53] 































Melchiorre (2016) [55] 
C, cross sectional and L, longitudinal. CO, cardiac output; SVR, systemic vascular resistance; MAP, mean arterial pressure; SV, stroke volume and HR, heart rate. 
Hemodynamic parameters from cross sectional studies presented as mean or median values. #Del Bene: SV calculated as left ventricular end-diastolic volume – left 
ventricular end-systolic volume. §&Turan: § = parous women and & = nulliparous women.  
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30 C Left lateral 16-38 7.45   94.22 80.9 Lechner (1978) [56] 
19 L Left lateral 8-40 6.8 -5.0   90-65  Atkins (1981) [57]  
14 L Supine 15-40 7.2-6.6  82-90 103-86 71-76 Myhrman (1982) [58] 
20 C Left lateral 45° 36-40 6.6 869.0 70.8 93.2 71 Milsom (1984) [59] 
49 L Left lateral 5-41 5.32-4.55 1341-1912  67.3-54.2 79-84 Heilmann (1993)# [60] 
50 L Sitting 10-42 7.26-6.37 966-1118 87-86 85-70 87-92 van Oppen (1996) [61] 
18 C Left lateral  37  7.07 827.75 71.5 80 84.06 San-Frutos (2005) [62] 
100 C Left lateral 36-39 6.8   79.7 86.1 Tamás (2007) [63] 
20 L Not described 10 - >30 6.91-5.76 918.40-1244.00 78-86 92.53-65.31 74-88 Moertl (2009) [64] 
53 L Supine 45° 22-40 5.5-5.8 1112-1179 78-87 74-70 75-82 Flo (2010) [7] 
103 C Lateral  38 6.10 1103.27 88.05 65.13 95.25 Jia (2010) [65] 
48 L Left lateral 12-35 6.7-5.9  74.5-80.6 89.6-71.3 75.9-84.7 Moertl (2012) [66] 
26 C Left lateral ≥ 32 6.4 921  84  Burlingame (2013) [51] 
28 L Supine 45° 12-36 7.0-7.0 911-946   89.5-79.1 81-90 D’Silva (2014) [67] 
32 C Supine 45° 22-24 6.12 1020.63 80.23   Flo (2014) [68] 

























Morris (2014) [70] 
218 C Standing 12 7.1  85 75 94 Oben (2014) [71] 
108 C Supine 45° 22-24 6.61 938.61 78.88 84.16  81.17 Vårtun (2014)*  
22 C Standing 37 7.3  99.5 77.5 97 Gyselaers (2015) [72] 
47 C Supine 45° 39 7.8 893 84 98 80 Marques (2015) [73] 
29 C Left lateral 37 6.1   83.1 74.2 McIntyre (2015) [54] 
98 L Supine 45° 20-40 6.58-7.11 956.73-971.22 80.10-86.56 82.97-81.68 82.13-90.37 Vårtun (2015)**  
557 C Supine 45 22-24 6.26 993.34 78.66 80.73 79.91 Vårtun (2015)*** 
C, cross-sectional study and L, longitudinal study. PLR, passive leg raising. CO, cardiac output; SVR, systemic vascular resistance; MAP, mean arterial pressure; SV, 
stroke volume and HR, heart rate. #Heilman: CO calculated from SV and HR given in the manuscript. *Vårtun: paper I; **Vårtun: paper II and ***Vårtun: paper III.    
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In early pregnancy there is a significant fall in mean arterial pressure (MAP) and SVR. These 
alterations are also shown in the mid-luteal phase even before pregnancy occurs [74]. As a 
response to the fall in SVR, the CO, HR and SV increase already from 5 to 8 weeks of gestation 
[6, 25, 29, 33, 75-77]. Circulating blood volume increases by approximately 50%. The increase 
in plasma volume is larger than the increase in the red cell mass resulting in a physiological 
hemodilution [8, 75, 77-79]. Hytten and Paintin observed a gradual increase in plasma volume 
reaching a plateau of 1250 ml above non-pregnant level in the third trimester [75]. Pirani et al 
found a 40 % increase in plasma volume from 2635 ml at around 12 weeks to 3700 ml at 30-34 
weeks among 56 primigravidae [79]. Similar observations were made by others reporting an 
increase in plasma volume from gestational weeks 6-8 until 28-30 weeks [9, 80]. The 
cardiovascular responses in early pregnancy result in decreased afterload and increased preload 
persisting until approximately the end of the second trimester. Thereafter, the hemodynamic 
variables remain relatively stable or fall slightly until term [6, 26, 81, 82]. Failure to increase 
plasma volume is probably involved in the development of complications such as pre-eclampsia 
(PE) and intrauterine growth restriction (IUGR) [83]. The maternal cardiovascular changes and 
adaptations during pregnancy are necessary to maintain adequate utero-placental perfusion, 
which is essential to supply the growing fetus with oxygen and nutrition [2, 9, 82]. 
3.1 Blood pressures 
The ability to perfuse the maternal organs and the feto-placental unit depends on the maternal 
blood pressure, which is the product of CO and SVR [2]. MAP represents the average blood 
pressure during the cardiac cycle, and is calculated as DBP + (SBP-DBP)/3, where DBP is 
diastolic blood pressure and SBP is systolic blood pressure. Maternal blood pressure decreases 
by approximately 10% at 7-8 weeks of gestation reaching the lowest value (nadir) at gestational 
weeks 16-20 [26, 33, 77]. Other reports have shown that the blood pressure and the SVR fall to 
a nadir at 22-24 weeks of gestation [7, 33, 81]. DBP decreases significantly until 20 gestational 
weeks, then rises progressively towards term, whereas SBP is relatively constant until 36 weeks 
of gestation [26]. Clark et al observed no significant difference in MAP between pregnant 
women at 36-38 weeks of gestation and non-pregnant women 11-13 weeks postpartum [19]. 
During early pregnancy, the hormonal milieu is changed with an elevation of progesterone level 
and secretion of local mediators such as prostaglandins and nitric oxide (NO) exerting a 
vasodilatating effect on the arterial and venous vasculature [29, 81]. The atrial compliance is 
increased leading to a decrease in SVR to accommodate for the increased blood volume [84]. 
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Chapman et al found that arterial vasodilation stimulates activation of renin-angiotensin-
aldosterone system resulting in a decrease of SVR [74]. 
3.2 Heart rate 
The heart rate increases from about 5 weeks of gestation [6, 29] throughout pregnancy as a 
compensatory response to the decrease in SVR [6, 26, 29, 31]. In a longitudinal study, Mabie 
et al found an increase in HR by 29% from the first to the third trimester [31]. Hunter and 
Robson, and Flo et al report a maximum increase of HR at 32 and 34 weeks, respectively, with 
a slight decrease towards term [6, 7]. Mahendru et al made similar observations, and they found 
a significant increase of HR until the third trimester by about 13 beats per minute [82]. The HR 
was significantly higher among multiparous women compared to nulliparous women, and HR 
reversed to pre-pregnancy level at 14-17 weeks after delivery [82]. Clapp and Capeless found 
that the heart rate returned to baseline level at 12 weeks postpartum [33]. 
3.3 Stroke volume 
The SV increases from eight to 20 weeks of gestation to approximately 20-30% above the non-
pregnant values [6, 25, 29, 33]. Clapp and Capeless observed a maximum increase in SV to 97 
ml at 24 weeks [33]. During the third trimester of pregnancy, the SV is relatively stable or 
slightly lower towards term [6, 29, 33]. 
3.4 Cardiac output  
CO increases by 40-50% above non-pregnant values from 5 weeks of gestation reaching 
maximum at 28-32 gestational weeks [6, 13, 17, 26, 29]. The increase in CO is approximately 
1.5 L above the pre-pregnancy values [11], resulting from an increase in HR and SV [6, 33, 34, 
81]. There are conflicting observations regarding changes in CO from the second half of 
pregnancy until term. Some authors have reported a steady state [6, 33] whereas others report 
a steady increase towards term [22]. In a longitudinal study, Flo et al found that CO increased 
significantly from 5.5 L/min at 22 weeks to 5.8 L/min at 34 weeks of gestation with no further 
change until term [7]. Others have found a decrease of CO in the second half of normal 
pregnancies until term [13, 29, 34]. The variation in absolute values of CO may be explained 
by inter-individual differences among pregnant women, maternal position during investigation, 
study design and method used to measure the CO [22, 85-87]. In addition, several studies have 
estimated changes of CO using postpartum values at various time intervals to represent non-
pregnant values [52]. 
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Clapp et al investigated 30 healthy women before pregnancy, throughout gestation and 12, 24 
and 52 weeks postpartum [33]. They found significant differences between pre-pregnancy CO 
and lower CO values in pre-pregnancy state compared to postpartum [33]. The observed 
reduction of CO during investigation in the supine position in late pregnancy may result from 
compression of inferior vena cava by the enlarged uterus causing reduced venous return to the 
heart [88, 89]. Approximately 5% of women experience hypotension in the flat supine position 
during late gestation with symptoms of dizziness, headache or nausea [88]. 
3.5 Systemic vascular resistance 
SVR is affected by changes in blood volume, vessel diameter and viscosity of the blood, all of 
which are affected by pregnancy. A study from Robson et al has shown a progressive fall of 
SVR by 34% from early pregnancy (5 weeks) to 20 gestational weeks in accordance with 
reduction in the DBP [26]. They observed a small increase of SVR towards term [26]. Other 
studies have reported similar reduction of SVR from six gestational weeks, reaching a nadir 
between 14 and 24 weeks of gestation, followed by an increase to pre-pregnancy values towards 
term [7, 13, 19, 29, 33, 81, 90]. Flo et al demonstrated an increase of SVR from gestational 
weeks 22 until term [7]. The plasma volume increases in pregnancy, but the CVP and the 
pulmonary capillary occlusion pressure (PAOP) remain unchanged [19]. This might be a result 
of reduced SVR and ventricular dilatation due to increased end-diastolic volume (preload). 
Summary of results of CO, SVR, MAP, SV and HR from previously published studies are 
presented in Table 1, 2, 3 and 4. 
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Ueland (1969) [17] 
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Echo Left lateral 
Supine 
40  5.88 
4.63 




Rubler (1977) [21] 
19 L  
 














































































Milsom (1983) [91] 
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Table 4: Continuation. 




Method Position Gestation 
(weeks) 
CO     
(L/min)  
range 
SVR        
(dyne s/cm5)  
range 
MAP     
(mmHg)   
range 
SV            
(ml)         
range 
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Seated 60º 






 Burlingame (2013) [51] 
28 L 
 























D’Silva (2014) [67] 
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Method Position Gestation 
(weeks) 
CO     
(L/min)  
range 
SVR         
(dyne s/cm5)  
range 
MAP     
(mmHg)   
range 
SV            
(ml)         
range 
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Vårtun (2014)*  
447 C 
 
ICG Supine 45° 
PLR 45° 
PLR left lateral 





















Marques (2015) [73] 





























Vårtun (2015)**   


















Vårtun  (2015)*** 
Dye, dye dilution; Echo, echocardiography; ICG, impedance cardiography and CMR, cardiac magnetic resonance. C, cross-sectional and L, longitudinal. PLR, 
passive leg raising. CO, cardiac output; SVR, systemic vascular resistance; MAP, mean arterial pressure; SV, stroke volume and HR, heart rate. Hemodynamic 
parameters from cross sectional studies given as mean or median values. *Del Bene: SV calculated as left ventricular end-diastolic volume – left ventricular end-




3.6 Cardiac function in pregnancy 
Pregnancy causes structural changes of the heart induced by altered preload, afterload and HR 
[81]. The increased blood volume following a rise in venous return and venous filling leads to 
an increased stretching of cardiac muscle fibers before contraction. The left ventricle (LV) mass 
and wall thickness increase from 12 weeks of gestation until the third trimester [22, 26]. The 
structural changes of the LV cause alteration of the heart’s position. The elevated diaphragm 
due to the enlarged gravid uterus pushes the heart upwards and rotates it forwards [94, 95]. 
Echocardiographic studies using Doppler have shown that the LV wall is thickened and the 
cardiac mass increased during pregnancy [22, 26, 96]. Robson et al observed a progressive 
increase in both LV mass and thickness from gestational weeks 12-38 by 52% and 28% above 
pre-pregnancy values, respectively [26]. Kametas et al report similar results; they found 52% 
increase in LV mass, and LV end-diastolic and end-systolic diameters increased by 12% and 
20%, respectively [97]. In addition, they found a 40% increase in left atrial diameter, 12% 
increase in LV end-diastolic diameter, and a 20% increase in LV end-systolic diameter during 
gestation compared to non-pregnant. Simmons et al found in their study among normotensive 
women that the LV wall thickness increased by 11% during pregnancy [96]. Similar results 
were reported by Estensen et al, who observed a slight increase in LV wall thickness from the 
second to the third trimester [52]. They found an increase of 23% in LV EDV with a decrease 
of 11% in LV EF indicating that the LV contractility is reduced during normal pregnancy. Other 
studies report different results regarding to the heart’s contractility during pregnancy. Mone et 
al and Geva et al also report decreased cardiac contractility during pregnancy [34, 98]. Two 
other studies report increased cardiac contractility during pregnancy [21, 35]. Clark et al 
observed that pregnancy is not associated with hyperdynamic LV function [19], and recently 
Melchiorre et al showed that the remodeling of the heart with a hypertrophy of the LV maintains 
the performance of the LV and the myocardial oxygenation in pregnancy [84]. 
Analysis of systolic time intervals such as the left ventricular ejection time (LVET) and the pre-
ejection period (PEP) provide information about the function of the left ventricle and the cardiac 
performance. LVET and PEP represent the duration of left ventricular ejection (mechanical 
systole) and the phase of isovolumetric ventricular contraction time (electrical systole), 
respectively [71]. The systolic time ratio (STR) is defined as the ratio of PEP and LVET (STR 
= PEP/LVET). Burg et al found that PEP decreased from the first to the second trimester [99]. 
Thereafter, they observed an increase towards term. LVET decreased throughout pregnancy. 
Katz et al observed similar reduction of LVET [22]. Liebson et al found that PEP increased and 
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LVET decreased during gestation [100]. These two variables relating to the systolic time 
intervals indicate decreased cardiac contractility among normotensive women during 
pregnancy. All three studies showed an increase in LVET during postpartum period. Burg et al 
and Liebson et al report contrasting results regarding PEP in postpartum period, showing an 
increase and a decrease, respectively [99, 100]. Estensen et al observed reduction of LV 
contractility during normal pregnancy due to reduced LVET and ejection fraction compared to 
6 months postpartum [52]. Their findings suggest that pregnancy induces a larger load on the 
cardiovascular system than previous studies have assumed. Other variables have been used to 
describe cardiac contractility and systolic function using impedance cardiography, such as the 
acceleration index (ACI), the velocity index (VI), and left ventricle work index (LCWI) 
representing cardiac work [51, 65, 69, 71]. 
3.7 Utero-placental circulation 
The left and right uterine arteries originate from the internal iliac arteries, supply the uterus and 
form anastomoses with the respective ovarian arteries. The uterine arteries branch into arcuate 
arteries, then into radial arteries, and finally into spiral arteries penetrating the outer and middle 
thirds of the myometrium [101, 102]. Approximately 80 % of the total utero – placental blood 
flow comes from the uterine arteries [103]. 
Development of placenta starts with the trophoblast cell lineage 4-5 days after conception. As 
pregnancy advances, the trophoblast cells further differentiate into specialized subtypes such as 
multinucleated syncytiotrophoblasts and mononuclated cytotrophoblasts [104, 105]. Following 
this, a fluid-filled space occurs within the syncytiotrophoblast layers forming a large lacuna that 
surrounds the embryo. The syncytium enables invasion and implantation into the interstitium 
of the endometrium (decidual stroma), thereby establishing direct contact with the maternal 
blood cells [104]. Thereafter, the cytotrophoblast cells differentiate into villous structures as 
chorionic villi protruding into the intervillous space [104]. The chorionic villi continue to grow 
throughout the pregnancy causing an increase in placental mass and surface, to secure adequate 
exchange of gases, nutritional substrates and metabolic waste products between the fetus and 
the mother [106]. The extravillous trophoblast cells invade and replace the endothelial and 
muscular layer of the maternal spiral arteries [102, 104]. Following this, the spiral arteries open 
into the intervillous space allowing the maternal blood flow to the fetus. The trophoblast 
invasion is complete at 18-20 weeks of gestation [107]. Physiological changes resulting from 
spiral artery remodeling by the trophoblast cells and subsequent vasodilatation cause increased 
artery diameter and reduced vascular resistance [103, 105, 108].  
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3.8 Utero-placental Doppler indices 
Indices related to the blood flow of the uterine arteries (UtA) such as pulsatility index (PI), 
resistance index (RI) and systolic /diastolic ratio (S/D) have been used to predict risk of adverse 
pregnancy outcomes such as PE, IUGR, and placental abruption. These indices are calculated 
from the Doppler derived blood flow velocity waveforms of the UtA and increased values of 
these indices have been implied to be surrogate measures of increased uterine vascular 
resistance [109]. Diastolic notching in the early diastolic phase of the cardiac cycle in the UtA 
waveform is another indirect sign of reduced blood flow and increased UtA vascular resistance 
[110]. An increase of UtA PI or RI, and unilateral or bilateral notching may indicate an 
increased risk of developing pregnancy complications [111]. However, UtA notching may be a 
normal finding in the first trimester before the utero-placental circulation is fully established 
[112]. 
Several studies have used Doppler ultrasonography in the evaluation of UtA blood flow pattern 
to obtain information about the utero-placental circulation [113, 114]. The reduction in 
impedance to flow in the UtA during pregnancy reflects trophoblastic invasion of the spiral 
arteries and their conversion into low-resistance vessels [115]. Campbell et al were the first to 
report the use of Doppler ultrasonography of the UtA to identify risk of pregnancy 
complications [116]. There are discrepancies between studies regarding the value of UtA 
Doppler indices in predicting pregnancy outcomes. This might be due to differences in 
measurement techniques, the definition of abnormal blood flow velocity waveform pattern and 
cut off values of indices used [117]. Previous studies have used different cut-offs or percentiles 
values of PI or RI together with or without bilateral notches for screening women for the risk 
of developing pregnancy complications. Papageorghiou et al found that 2.2% of pregnant 
women developed PE with a mean UtA PI >1.6 (95% percentile), and the presence of bilateral 
notches were highly associated with high PI when examined during 22-24 weeks of gestation 
[118]. Rizzo et al found that 4.7 % of pregnant women at 20-24 weeks with mean PI >1.63 and 
bilateral notches developed PE [119]. Abnormal uterine artery blood flow is a good predictor 
of early-onset PE, but has limited value in predicting late-onset PE [120]. Measurements 
performed in the second or third trimesters have a higher predictive value than those performed 
in early pregnancy. Among women with pre-existing cardiac disease a higher incidence of 
abnormal UtA flow is found, as the utero-placental flow probably depends on maternal cardiac 
performance [121]. 
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4 PLACENTAL DYSFUNCTION DISORDERS 
Placental dysfunction can cause miscarriage, hypertensive pregnancy disorders, gestational 
diabetes, intra-uterine growth restriction and fetal death. These conditions have long-term 
consequences for the mother and her offspring. 
4.1 Hypertensive disorders 
The hypertensive disorders of pregnancy include gestational hypertension, pre-existing chronic 
hypertension, PE and eclampsia [122]. 
4.2 Gestational hypertension 
Gestational hypertension is characterized by an increase of maternal SBP and DBP ≥ 140/90 
mmHg, measured at least two times 4-6 hours apart after 20 weeks of gestation [123-126]. 
Blood pressure ≥ 140/90 mmHg before 20 weeks of gestation is defined as chronic or pre-
existing hypertension, and the risk of adverse pregnancy outcome is increased [124, 127]. Blood 
pressure ≥ 160/110 mmHg for at least 6 hours is considered to be severe hypertension [128]. 
4.3 Pre-eclampsia 
PE is a complication affecting 2-8% of pregnant women worldwide, and is characterized by 
new onset of hypertension with proteinuria after 20 weeks of gestation [123, 129]. Proteinuria 
is defined as urine protein concentration of 300 mg/L or more (≥1+ on dipstick) at least on two 
occasions and 4-6 hours apart [123, 124]. PE can affect several organs including kidney, liver, 
brain and the clotting system [42, 106, 124, 130-132]. The disorder is a major cause of maternal 
and perinatal morbidity and mortality [42, 106, 123, 124, 130, 133]. Maternal deaths from pre-
eclampsia and eclampsia account for up to 15% of maternal mortality, and it is 100 to 200 times 
higher in developing countries (Africa and Asia) than developed countries (Europe and North 
America) [130, 134]. The rate of PE in developed countries vary from 1.4% to 4%, and the 
overall risk of developing PE in Norway is 3.6% [135, 136]. 
PE causes changes in maternal hemodynamics. The SVR is increased and CO is often lowered 
compared to normotensive pregnancy [53, 90]. The pathogenesis of PE is currently thought to 
arise from placental dysfunction affecting the maternal endothelium resulting in systemic 
vascular complications [106, 131, 137]. Several acute maternal complications can evolve 
following PE including eclamptic fits, stroke, placental abruption, HELLP syndrome 
(hemolysis, elevated liver enzymes, and low platelets), pulmonary edema, liver hemorrhage or 
rupture, renal failure and death [134]. Neonatal complications from PE include preterm 
delivery, IUGR, hypoxia, neurologic injury and perinatal death depending on gestational age 
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and severity of the disease [123]. Pre-eclampsia is a heterogeneous condition, and term PE 
probably includes different diseases. Early-onset PE is defined as onset before 34 weeks of 
gestation, and late PE when the condition is diagnosed after 34 gestational weeks [48]. Early-
onset PE is often associated with placental abnormality due to insufficient utero-placental blood 
flow. IUGR, premature delivery, and severe maternal morbidity are associated with the early-
onset form of PE [48, 106, 125, 131, 138, 139]. Late-onset PE is considered to be superimposed 
upon a pre-existing maternal cardiovascular condition such as high blood pressure, diabetes or 
various organ diseases [140]. Approximately 80 % of PE worldwide, is late onset PE associated 
with an appropriately grown baby [138]. A previous study by Valensise et al observed 
significantly higher CO and lower TVR among women with late onset PE compared to early 
onset PE [48]. Risk factors for developing PE are previous PE, pre-existing hypertension, 
primiparity, maternal age < 18 or > 40 years, multiple pregnancy, renal or rheumatic disease, 
obesity and a family history of hypertensive disorders of pregnancy [120, 123, 131, 141, 142]. 
However, more than 50% of the women who develop PE have no risk factors in their history, 
and many women with risk factors mentioned above do not develop the disorder. Women 
developing PE are at increased risk of cardiovascular diseases (CVD) later in life, and additional 
risk factors such as high levels of cholesterol, glucose and abdominal obesity increase the 
remote risk for CVD further [132, 143-145]. The causes of PE are unknown, and currently there 
are no precise criteria for prediction or prevention of PE [106, 123, 131, 139]. Early 
identification of women at risk for developing PE is crucial to assure adequate antenatal care 
and eventually prophylactic treatment [146]. Delivery and removal of the placental tissue is the 
only definite cure [137]. 
4.4 Intrauterine growth restriction 
A fetus or neonate is defined as small for gestational age (SGA) when the (estimated) weight is 
below a certain percentile, usually the < 10th percentile [147]. The majority of these babies are 
healthy and only constitutionally small. During pregnancy they will generally grow 
appropriately although in the lower percentiles [4]. 
IUGR is characterized also by low birth weight, most commonly defined as weight < the 10% 
percentile. These fetuses have failed to reach their genetically determined growth potential. 
There is often asymmetric growth with an abdominal size that is smaller compared to the size 
of the head, and the fetal growth is slower than expected. Mostly, IUGR is caused by placental 
insufficiency and the umbilical (and/or UtA) Dopplers are usually abnormal [113]. 
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5 METHODS OF ASSESSING MATERNAL CARDIOVASCULAR 
FUNCTION 
Different methods have been used to investigate systemic hemodynamics and cardiac function 
in pregnant women, and to monitor critically ill patients. Two basic categories are available, 
invasive and non-invasive methods. In clinical settings both methods are used. Non-invasive 
methods are more appropriate for research purposes among especially in healthy pregnancies. 
5.1 Invasive methods 
5.1.1 Fick principle 
The Fick principle was first described and developed by Adolf Eugen Fick in 1870 and used 
for the assessment of CO. The method has been described as the “gold standard” for 
determination of CO, based on oxygen consumption by an organ by calculating the difference 
between the arterial (A) and the venous (V) oxygen content. 
Oxygen is the most commonly used marker in the determination of CO. The oxygen consumed 
over time is calculated from measurement of oxygen concentration of venous and arterial blood 
using the Fick’s equation; VO2 = (CO x CA) – (CO x CV), where VO2 is oxygen consumption 
in ml of pure gaseous oxygen per minute, CA is oxygen concentration of arterial blood, CV is 
oxygen concentration of mixed venous blood. From these measurements cardiac output can be 
calculated as; CO = VO2 / (CAO2 – CVO2), where (CAO2 – CVO2) is the arteriovenous oxygen 
content difference [148, 149]. Among critically ill patients who are hemodynamically unstable, 
and need breathing assistance, expired air measurement and arterial blood sampling are 
necessary for the determination of CO. It is one of the most accurate techniques when the CO 
is low, but requires repeated measurements, and is not very practical in clinical and research 
settings. 
5.1.2 Dye indicator dilution 
During the 1890’s, Stewart introduced an indirect method for determination of CO [150]. Later 
Hamilton refined this technique. The technique is based on injection of a known amount of an 
indicator dye into one site of the circulatory system, and the measurement of the concentration 
of the dye at another site after certain time intervals. Then a dilution curve of the dye can be 
constructed, from the concentration of the dye obtained at different time intervals. Cardiac 
output is calculated from the time-concentration plot by using the equation: CO = (I x 60)/(C x 
t), where I is the amount of dye injected (mg), 60 is conversion factor from seconds to minutes, 
C is the mean concentration of dye (mg/L) during curve duration, t is time during curve duration 
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in seconds [151]. This method is more accurate when the CO is high. The drawbacks of this 
method are the need for multiple blood samples and a device for measuring of the concentration 
of the indicator. 
5.1.3 Thermodilution  
The thermodilution technique to measure CO was first described in the 1950’s [152]. In the 
1970’s this method was shown to be reliable and reproducible by Swan and Ganz using a 
temperature sensing pulmonary artery catheter (PAC), known as the Swan-Ganz catheter. The 
method is based on the indicator dilution principle measuring temperature change of the 
indicator as heated or cooled fluid. A solution with known temperature is injected rapidly into 
the pulmonary artery via a catheter. This provides direct access to the right heart. The 
temperature of the blood is measured downstream at a known distance in the pulmonary artery 
by a thermistor bead embedded in the same catheter. CO is determined from a time-temperature 
change curve using the modified Stewart-Hamilton equation; CO = (Ta-Tb) x VI x K /ƒdT/dt, 
where Ta is the temperature before injection, Tb is the temperature after injection, VI is the 
volume of the injected substance, K is a constant, and dT/dt is the change in temperature per 
change in time [148]. Calculation of CO from a measured time-temperature curve shows 
reproducible values, as the degree of temperature change is directly proportional to the CO. A 
slow temperature change indicates a low CO; a rapid shift of temperature indicates a high CO, 
and averaging repeated measurements improves the accuracy of the method. Swan-Ganz 
thermodilution method is a useful tool for clinicians and it is used in the assessment and guide 
management of critically ill patients. The method is referred to as the clinical “gold standard” 
method of hemodynamic monitoring when new technologies are compared and validated. 
5.2 Noninvasive methods 
Noninvasive methods are simpler to use and constitute less risk compared with the invasive 
methods. Such techniques offer assessment of absolute values as well as trend analysis of 
cardiac output and other hemodynamic variables. 
5.2.1 Impedance cardiography 
The ICG technique, also referred to as thoracic electrical bioimpedance, has been used for the 
last 50 years to measure hemodynamic and cardiovascular variables [153, 154]. This technique 
is based on changes in the thoracic impedance during the cardiac cycle. The method measures 
SV and other cardiovascular parameters including cardiac contractility directly [51, 81, 155]. 
The basic principles of ICG were established in Russia during the 1940s, and improved during 
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the 1960s when it was used to measure CO among astronauts in a space program. In 1966 
Kubicek et al. introduced the four-electrode impedance system using aluminum band electrodes 
applied around the abdomen and neck as the cylinder model to calculate SV from the original 
equation [156, 157] as: SV = p x L2 / Z0
2 x (dZ/dt) max x LVET, where p is a constant for the 
electrical resistivity of blood, L represents the mean distance between the two inner electrodes 
(cm), Z0 is the basic impedance between the two inner electrodes (ohms), (dZ/dt) max is the 
maximum value of the first derivative of the impedance waveform and LVET is the LV ejection 
time [155, 156].  
Later, Sramek modified Kubiceks’ equation considering the chest as a truncated cone [158], 
and proposed a new formula to calculate SV as: SV = (0.17 x H) 3 / 4.2 x (dZ/dt) max / Z0 x 
LVET, where the constant L in the above equation is approximated as 17 % of the height (cm) 
in a normal adult. Bernstein further modified the equation by adding a weight correction factor, 
δ, representing the modified ratio of the observed weight to the so-called ideal weight [159]. 
This modification would determine a more correct volume of the thorax [153, 156, 159] as 
follows: SV = δ x (0.17 x H) 3 / 4.2 x (dZ/dt) max / Z0 x LVET. 
The ICG technology has recently been improved further by more advanced data processing and 
software [51, 153, 155, 156, 160]. ICG is painless, without risk, operator independent, and has 
the ability to obtain continuous hemodynamic data and allows evaluation of trends and changes 
of cardiovascular variables over time by performing repeated measurements [51, 153, 160]. 
5.2.2 Bioreactance 
Bioreactance is a new noninvasive technique similar to ICG using an electrical current of low 
amplitude with known frequency applied on the chest between two leads [161]. This technique 
is based on detection of the relative phase shifts (frequency shifts) between the two leads, the 
applied current and the received signal, which is created due to changes in the blood volume of 
the aorta [162]. The advantage of this technique is that the frequency modulations and phase 
shifts are independent of the distance between the applied and detected signal. The SV is 
proportional to the product of ventricular time (VET), the maximum phase shift (dϕ/dt max) and 
a constant of proportionality is C [161, 162]: SV = VET x dϕ/dt max x C. There are only few 
published studies with small sample sizes using this method. 
5.2.3 Echocardiography 
Echocardiography combined with Doppler ultrasound has been in use since the 1980s for 
investigation of hemodynamics and cardiac function. This method is widely used in the 
diagnosis and management of patients with cardiac diseases as well as in clinical research [38, 
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163]. For measuring the CO, the diameter of the aorta is measured at the aortic valve level, and 
the aortic cross-sectional area (CSA) is calculated as: CSA = π (D/2) 2, where D is the diameter 
of the aorta [76, 164]. Transthoracic Doppler ultrasound is used to measure blood flow velocity 
at the aortic valve during systole, and the time velocity integral is measured (VTI) [23, 161]. 
Then the SV is determined from the formula: CSA x VTI. CO is calculated as SV x HR. 
Measurement of CO with echocardiography correlates well compared with the invasive “gold 
standards” i.e. thermodilution and Fick methods by a correlation coefficient of 0.91 and 0.93, 
respectively [23, 76]. Lee et al found that the correlation between echocardiography and 
thermodilution performed among pregnant women was 0.94 for CO and 0.86 for SV [165]. 
Easterling et al observed a correlation coefficient of 0.92 between different operators for CO 
measurements ([166]. A study by Robson et al shows a high reproducibility of 3.1-3.7% within 
patient [76]. One limitation of Doppler echocardiography is that it does not provide continuous 
hemodynamic measurements [161]. Another limitation is that Doppler echocardiography is 
operator-dependent, and requires a trained operator to obtain correct measurements of the vessel 
diameter and the blood flow velocity [164]. However, Doppler ultrasonography is not very 
difficult to learn, and it is a useful tool in studying hemodynamics, as well as identifying and 
monitoring heart diseases in clinical settings [161, 164]. 
5.2.4 Cardiac magnetic resonance 
The cardiac magnetic resonance imaging (CMRI) is a method that is increasingly used for the 
diagnosis of cardiac disease and evaluation of the cardiovascular system [167, 168]. The CMRI 
technique is based on strong magnetic fields and radio waves converting echoes from released 
energy into images, and combining sequences of electrocardiography (ECG) at each stage of 
the cardiac cycle from multiple cardiac cycles displaying cardiovascular function as cine 
imaging loops [168]. Assessment of cardiac blood flow can be performed in a single scan with 
good image quality compared to transthoracic echocardiography (TTE), which requires several 
assumptions for evaluation of systemic hemodynamics [93]. 
Until now, few studies have been published using the CMRI in the evaluation of maternal 
hemodynamics and cardiac function during pregnancy [92, 93, 169]. Ducas et al found good 
correlation between the CMRI and TTE measured SV and CO among women in the third 
trimester, but reporting consistently lower values for TTE compared to CMRI [169]. 
The advantage of CMRI is the fast imaging combined with good quality images. Safety, 
accuracy and reproducibility of CMRI are comparable to echocardiography [169]. Investigation 
using CMRI requires an experienced and skilled operator and expensive equipment and 
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repeated measurements may not be practical. However, this non-invasive method can be useful 
in the assessment of pregnant women with pre-existing or suspected cardiac disease or 
pregnancy complications. 
5.2.5 Gas re-breathing technique 
Investigation and assessment of CO can also be performed using the gas re-breathing technique 
[170]. This method is used for measuring effective pulmonary blood flow (QEP) that in the 
absence of intrapulmonary shunt flow is equivalent to CO [170]. The system consists of an 
accurate infrared photo acoustic gas analyzer continuously analyzing gas concentrations of the 
ventilator. It is a closed system including a mouthpiece with a three-way respiratory valve and 
a re-breathing bag that is connected to the gas analyzer. The re-breathing bag contains a gas 
mixture of blood-insoluble gas, N2O, and O2 in N2. The software of the gas analyzer calculates 
the QEP from the rate of uptake of N2O into the blood. Then CO is determined according to the 
formula as: CO = QEP + shunt flow, where the shunt flow is based on shunt fraction of O2 
content in arterial and mixed venous blood samples. This method might be useful in assessing 
patients with cardiovascular diseases such as pulmonary hypertension and heart diseases as well 
as for cardiovascular research [170]. 
5.3 Functional hemodynamics 
Previous studies evaluating cardiac function and systemic hemodynamics in different maternal 
body positions show differences both between methods and between studies using the same 
equipment (Tables 1-3). Variation in results from studies among pregnant women may reflect 
factors such as: inaccurate description of body position during examinations, differences in 
study design, gestational age, methods used and small number of participants. Some researchers 
describe the position just as left, right lateral or supine without precisely describing if the upper 







        
 
       
 
Figure 1. Different maternal positions during examination of cardiac function and systemic 
hemodynamics, left lateral (A), right lateral (B), supine flat (C), and supine semi-recumbent 
(D). 
Static measurements of hemodynamic variables are not sufficient to understand maternal 
cardiovascular adaptation in pregnancy. Therefore, investigations in different body positions 
(functional hemodynamics) have also been performed to evaluate the physiological 
cardiovascular response (Table 4). Functional hemodynamics in pregnant women may also be 
important to identify and monitor complications during pregnancy. Static measures of 
hemodynamic variables among critically ill patients have shown limitations in response to fluid 
therapy when change in SV was used to assess fluid responsiveness [171]. Fluid responsiveness 
is generally defined as a 10-15% increase in CO or SV [161]. Dynamic measurements perform 
better in evaluating fluid responsiveness (preload reserve) helping to unmask hypovolemia 
[161, 171]. 
Katz et al found a significant increase in SV from the first to the third trimester in the lateral 
position, but not in the supine position [22]. Lees et al on the other hand, reported a reduction 
in SV measured in the supine position compared to the lateral position in the late third trimester 
of pregnancy [172]. This difference between positions might be due to pressure of the gravid 
uterus on the inferior vena cava with a subsequent reduction of venous return. Using ICG, 
Myhrman et al measured 14% and 20% decrease in CO during early and late pregnancy, 
respectively when changing maternal position from supine to left or right lateral [58]. Milsom 
et al found a decrease of 17% in CO by posture change from lateral (45°) to supine [59]. Some 
other studies report no changes of CO during postural change in late pregnancy [7, 63]. 
Burlingame et al observed a decrease of CO as well as SV, and an increase of SVR by changing 





LVET was reduced throughout pregnancy, from first trimester to term, measured with 
echocardiography in the left lateral decubitus as well as in the supine position [22]. Change of 
body position from the supine to the standing posture may affect the cardiovascular system due 
to gravitational effect leading to decreased venous return as blood pools in the vessels of the 
lower part of the body. This leads to a reduction in blood pressure, which is followed by an 
activation of the baroreflex receptors to maintain pressure by increasing vascular tone and SVR. 
Easterling et al observed that the maternal CO decreased by 1.7-1.8 L/min both in early and late 
gestation with increasing orthostatic stress by changing body position from the left lateral 
recumbent to sitting and then to the standing positions [24]. Both HR and SVR increased by the 
change of body position [24]. 
Recently, several investigators have used passive leg raising (PLR) as a dynamic test to predict 
fluid responsiveness (preload reserve), particularly in intensive care units [173, 174]. PLR 
induces changes of CO and SV independent of breathing conditions. This method may be useful 
for assessing volume status and fluid responsiveness in pregnant women. It has been shown to 
be useful in monitoring fluid management in oliguric women suffering from severe 
preeclampsia [175]. 
 
6 AIMS OF THE STUDY 
The aim of this thesis was to investigate maternal functional hemodynamics in normal 
pregnancies and in pregnancies at risk of developing placental dysfunction disorders. 
The main objectives were: 
1. To investigate functional hemodynamic response to PLR in healthy pregnant women 
at 22-24 weeks of gestation and compare with non-pregnant women. 
2. To investigate cardiovascular response to PLR in healthy pregnant women and 
establish longitudinal reference ranges for the second half of pregnancy. 
3. To compare cardiac function, systemic hemodynamics and preload reserve among 
women with increased and normal UtA PI at 22-24 weeks of gestation.  
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7 MATERIAL AND METHODS 
7.1 Ethical approval 
The studies were approved by the Regional Committee for Medical and Health Research Ethics 
- North Norway (Ref. nr.5.2005.1386. Date of approval: 12.03.2010 (Paper I). Ref. 
nr.2010/575-2. Date of approval: 10.02.2010 (Paper II). Ref. nr.5.2005.1386 and 2010/586 
(Paper III). 
7.2 Study design 
The studies were prospective and observational. The cross-sectional studies (article I and III) 
were performed in the second trimester during 22-24 weeks of gestation. The longitudinal study 
(article II) was carried out on pregnant women from 20 weeks of gestation until term and 
examinations were performed at approximately 4-weekly intervals. 
7.3 Study population 
The study population consisted of 54 non-pregnant women of reproductive age and 826 
pregnant women. 
7.4 Non-pregnant women 
Healthy non-pregnant women of reproductive age were recruited from among the nursing, 
administrative and laboratory staff of the hospital and the university. They were asked to attend 
for hemodynamic assessment during the follicular phase between day 5 and 10 of the menstrual 
cycle. Exclusion criteria were women with a previous history of pregnancy complications or 
with a known disease, and those on regular medication. Examinations were performed in a non-
fasting state. 
7.5 Pregnant women 
The pregnant women attending the antenatal clinic at the University Hospital of North Norway 
for routine ultrasound screening at 17-20 weeks of gestation were recruited to the study. They 
were informed about the study and invited to participate if they were aged >18 years, had a 
singleton pregnancy and the ultrasound scan did not show any fetal or placental abnormality. 
Multiple gestation and inability to communicate in Norwegian or English were exclusion 
criteria. Additionally, in study I and II, only women with low risk pregnancy were included and 
those with a previous history of PE, gestational diabetes, IUGR and preterm delivery were 
excluded. Examinations of the participants were performed during 8:00 to 14:00 hours in a quiet 
room with ambient temperature maintained at approximately 22 degree Celsius. 
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8 METHODS  
8.1 Anthropometry 
Height was measured in centimeters using an altimeter (Charder Electronic Co, Taichung City, 
Taiwan). Body weight was determined by weighing the woman on a precision scale (Soehnle, 
Leifheit AG, Nassau, Germany) in light clothing without shoes. The weight was recorded to in 
kilograms. Body mass index was calculated as: weight/height2 and the body surface area (BSA) 
was calculated as: BSA = 0.007184 × height 0.725 × weight 0.425. 
8.2 Impedance cardiography 
Cardiac function and systemic hemodynamic variables were measured using ICG (Philips 
Medical Systems, Androver, MA, USA) together with a sphygmomanometer cuff placed on left 
arm connected to the ICG instrument. Height and weight of the participants were inserted in 
the machine before measurements were performed. The CVP and PAOP were preset to 4 and 8 
mmHg, respectively. Measurements were performed at baseline and after PLR. The participants 
were instructed not to move and speak during the measurements. Four pairs of sensors were 




                 
Figure 2. Assessment of maternal cardiac function and systemic hemodynamics using 
impedance cardiography (ICG) in a women at 29 weeks of gestation (upper) and a schematic 
representation showing placement of ICG sensors (four outer, purple and blue, electrodes 
transmit the current and four red inner electrodes detect the impedance signals). 
The blood pressure cuff is placed on the left arm. The measured variables are continuously 
displayed on the ICG screen (lower right). 
 
Two pairs of sensors were placed vertically on each side of the thorax at the anterior axillary 
line, whereas the other two pairs were placed on each side of the neck. The outer electrodes on 
the sensor are electrodes transmitting current through the chest to the aorta with the least 
resistance. The inner electrodes of the sensor are voltage electrodes measuring impedance 
signals that change as blood volume and velocity is changes with each heartbeat. Impedance 
changes together with electrocardiogram (ECG) and blood pressure measurements are used for 
the calculation of the systemic hemodynamic parameters. 
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The measurements were performed after approximately 10 minutes of rest in a supine 
recumbent position on an electronically steerable bed with the upper part of the bed at a 45° tilt 
(Figure 3A). Thereafter the upper part of the bed was lowered to a flat supine position and PLR 
was achieved by elevating both legs to a 45° tilt (Figure 3B). 
 
 
Figure 3. The position of the study participant during the assessment of systemic 
hemodynamics. A) Baseline measurement after 10 minutes of rest. B) Measurement after 90 
seconds of passive leg raising. 
 
The cardiac function and hemodynamic parameters (CO, HR, SBP, DBP, MAP, SVR, systemic 
vascular resistance index (SVRI), SV, stroke index (SI), TFC, ACI, LCWI, LVET and PEP) 
were continuously measured as displayed on the screen (Figure 2). Cardiac index (CI) was 
calculated as: CI = CO/BSA. 
LVET is the interval from the opening to the closing of the aortic valve, called the mechanical 
systole. PEP is the time interval from the beginning of the electrical stimulation of the ventricles 
to the opening of the aortic valve, called the electrical systole. Systolic time ratio (STR) is the 
ratio of electrical systole to mechanical systole: (PEP/LVET) x100 in percent. Acceleration 
index (ACI) reflects the maximum acceleration of blood flow in the aorta during systole. 
Velocity index (VI) is the peak velocity of blood flow in the aorta during systole. Left 
ventricular work index (LWCI) is the left cardiac work normalized to body surface area (BSA). 
BSA is calculated as: 0.0136 x (MAP-PAOP) x SV. Thoracic fluid content (TFC) is an indicator 
of the chest fluid status, denoted as 1/kOhm. 
8.3 Doppler ultrasonography of uterine arteries 
The blood flow velocity waveforms were obtained from the maternal UtAs using Acuson 
Sequoia 512 ultrasound system (Mountain View, CA, USA) with a 2.5-6 MHz curvilinear 
transducer. Doppler ultrasonography was performed keeping the exposure to ultrasound energy 
low according to the ALARA (as low as reasonably applicable) principle [176]. During 
examination the pregnant women were lying in a semi-recumbent position to avoid compression 
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of inferior vena cava by the gravid uterus. Color-directed pulse-wave Doppler was used for 
visualizing the UtAs. Blood velocity waveforms were recorded (Figure 4) from both UtAs (left 
and right) proximal to the apparent crossover with the external iliac artery. Three to six uniform 
Doppler velocity waveforms were recorded and online measurements of velocities were 
performed. UtA PI was calculated as: (peak systolic velocity – end-diastolic velocity)/time-
averaged maximum velocity. Values of three successive cardiac cycles were averaged and 
recorded. The PI values of the left and the right UtA was averaged and used for statistical 
analysis. Presence of bilateral or unilateral diastolic notch was also recorded. 
 
A           B 
  
 
Figure 4. Pulsed-wave Doppler images showing blood velocity waveforms of the uterine 
arteries (UtA). Normal UtA blood flow velocity waveform (A), and abnormal UtA blood flow 
velocity waveform with diastolic notch indicated by the red arrow (B). 
8.4 Outcome measures 
The participants had standard follow up during pregnancy and the course and outcome of 
pregnancy including information on the neonate was recorded in electronic medical records. 
The outcome data were obtained from all the participants. Information on any complications 
arising during pregnancy, mode of delivery, gestational age, birth weight, Apgar score, 
umbilical artery pH and base excess, and placental weight was recorded. In addition, 
information on neonatal outcome was also obtained. 
8.5 Statistical analysis  
The IBM Statistical Software for Social Sciences for Windows (SPSS, Inc., Chicago, IL, USA) 
was used for statistical analysis of cross-sectional data. Independent samples t-test was used for 
analysis of difference between groups. Continuous variables are presented as mean±standard 
deviation or median (range). Categorical variables are presented as n (%). Differences in 
proportions between groups were analyzed using chi-squared test. Comparison between 
baseline measurements and measurements obtained after PLR on the same individuals in each 
group was performed using paired sample t-test. 
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The Statistical Analysis Software, version 9.3 (SAS Institute INC., Cary, NC, USA) was used 
for statistical analysis of the longitudinal data. The number of study participants required to 
establish normal reference intervals was estimated to be approximately 100 based on the 
assumption that 20 observations per gestational week (i.e. a total of 400 observations between 
20-40 weeks) would be sufficient to calculate reference intervals with adequate precision [177]. 
Each variable was checked for normality. Logarithmic or power transformations were 
performed to achieve normal distribution as required. Fractional polynomials were used to 
obtain best fitting curves in relation to gestational age accommodating for nonlinear association. 
Multilevel regression modeling using proc mixed in SAS was used to investigate gestational 
age associated changes in functional hemodynamics and estimate the reference percentiles 
accounting for possible dependency between repeated measures [178, 179]. Individual 
observations were fitted as a linear function for the fractional polynomial term of time, i.e. the 
gestational age. A random intercept term for each individual and a random slope were included 
for the fractional polynomial term of gestational age. Statistical significance was set to a p-
value of <0.05. 
9 SUMMARY OF RESULTS 
9.1 Paper I 
Functional hemodynamic measurements may be more informative than just the static measures 
of cardiovascular function. We investigated functional hemodynamic response to 45° of PLR 
using impedance cardiography. A total of 108 healthy pregnant women were examined cross-
sectionally at 22-24 weeks of gestation using ICG and compared with 54 non-pregnant women. 
Parameters describing cardiac function and systemic hemodynamics were obtained at baseline 
and 90 seconds after PLR. Percent change in the value of measured variables from baseline to 
PLR represented the preload reserve. 
Static measurements of systemic hemodynamics and cardiac function at baseline were different 
between pregnant and non-pregnant women. The CO and SV were observed to be 27.6% and 
5.1% higher, respectively among healthy pregnant women, whereas the MAP and SVR were 
6.9% and 27.3% lower, respectively compared to healthy non-pregnant women. 
The variables describing cardiac contractility (ACI, VI, PEP, LVET) and work (LCWI) were 
statistically different between pregnant and non-pregnant women (p=0.050 to <0.001). 
PLR led to significant changes in the majority of hemodynamic parameters compared to 
baseline in both pregnant and non-pregnant women with similar trends. The SV increased by 
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2.15% (p=0.042) in pregnant women and by 2.44% (p=0.018) in non-pregnant women as a 
result of PLR, but the CO did not increase significantly in both groups. PLR caused a significant 
reduction in MAP and SVR (p<0.001 and p<0.005). 
We observed a reduction of cardiac contractility and work as assessed by ACI, VI, PEP and 
LCWI in both groups during PLR. The duration of ventricular ejection during systole 
represented by the LVET was significantly increased by PLR. 
The physiologic response to PLR was similar among pregnant and non-pregnant women. Less 
than 15% of the pregnant women were found to be preload responsive (i.e. had >10% increase 
in SV or CO in response to PLR) in the second trimester of pregnancy at 22-24 weeks. 
9.2 Paper II 
There are only a few studies with small sample size that have investigated hemodynamic 
responses to postural changes in healthy pregnant women (Table 4). We investigated maternal 
systemic hemodynamics at baseline and cardiovascular response to PLR serially during the 
second half of pregnancy. A total of 98 healthy pregnant women were examined approximately 
at 4-weekly intervals during 20+1 – 40+5 weeks of gestation (441 observations) and gestational 
age specific longitudinal reference ranges (graphs and percentile charts) were constructed 
(Figures 3 and 4 and Tables S2-S13). The variables describing maternal cardiovascular function 
were significantly associated with gestational age, except for CI and SVR. We found an increase 
of CO from 6.3 L/min at 20 weeks to 7.0 L/min at 37 weeks, remaining stable thereafter until 
term. The SV decreased from 83 ml at 20 weeks to 78 ml at term, the HR increased 
progressively during the second half of pregnancy, and the SVR remained stable. 
Maternal cardiovascular response to PLR was also significantly associated with gestational age. 
We observed a 1.2% reduction in CO at 24 weeks and 5.4% reduction at term compared to 
baseline values following 90 seconds of PLR. Whilst PLR led to an insignificant but small 
increase in SV from 20+1 to 31+6 weeks, thereafter the SV was slightly lowered by PLR 
compared to baseline until term. The SVR was also significantly altered by PLR showing a 
decrease until 31+6 weeks, and a slight increase thereafter until term. Our study showed that 
healthy pregnant women have limited preload reserve especially in the third trimester. We have 
established gestational age specific longitudinal reference ranges of maternal systemic 
hemodynamics (Tables S2-S13) and functional hemodynamic response to PLR during the 
second half of pregnancy (Figures 3 and 4, and Tables 5-16 in Appendix). 
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9.3 Paper III 
UtA Doppler velocity waveforms with PI and/or presence of early diastolic notching have been 
used to identify women at risk of developing pregnancy complications such as PE and IUGR. 
This has been shown to be a useful screening test especially in high-risk populations of pregnant 
women. However, this is not an effective screening tool in low-risk pregnancies. As many 
women who develop placental dysfunction disorders may have underlying cardiovascular 
predisposing factors, combining UtA Doppler with functional hemodynamic assessment might 
improve the predictive value of UtA Doppler. We examined 620 pregnant women at 22-24 
weeks of gestation using Doppler ultrasound to measure UtA PI and ICG to assess maternal 
systemic hemodynamics and cardiac function. Functional hemodynamic response to PLR was 
also evaluated by performing ICG at baseline in a supine semi-recumbent position and during 
PLR and pregnant women with increased UtA PI (mean PI ≥1.16), were compared to those with 
normal UtA PI  (mean PI <1.16). 
We observed that 17.5% of women with abnormal UtA PI developed PE compared to 3.8% of 
controls. The CO, SV and HR were not different between groups, but at baseline the SVRI and 
MAP were significantly higher in the abnormal PI group compared to controls. The 
cardiovascular response to PLR was similar in both groups at 22-24 weeks of gestations. The 
PLR led to slightly higher increase of SV among pregnant women with high UtA PI compared 
to women with normal UtA PI (3.4 ml versus 2.6 ml). We found 26.3% of women with high 
UtA PI to be preload responsive (i.e. increased SV by >10% following PLR) compared to 23.1% 
of women with normal UtA PI (p=0.656). 
10 DISCUSSION 
Assessing maternal hemodynamics can be useful in identifying women at risk of developing 
pregnancy complication as well as monitoring women with severe disease. However, static 
measures of cardiovascular function may not provide sufficient insight into changes in maternal 
hemodynamics occurring during pregnancy. Studies presented in this thesis were performed to 
investigate maternal functional hemodynamics to better understand the physiological 
cardiovascular adaptations that take place during the course of normal pregnancy and maternal 
functional hemodynamic profile in pregnancies at increased risk developing placental 
dysfunction disorders. 
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10.1 Preload reserve in pregnancy 
We found no differences in the magnitude or trend of response to PLR between non-pregnant 
women and healthy pregnant women at 22-24 gestational weeks. Our study showed that less 
than 15% of healthy pregnant women were preload responsive at 22-24 weeks of gestation, and 
the results were not significantly different compared to non-pregnant women. Volume depletion 
has been shown to increase preload reserve during PLR [180]. However, preload reserve seems 
to be low in well-hydrated individuals. Furthermore, increased circulating blood volume in 
pregnancy may cause an attenuation of baroreflex activity and increased tolerance of orthostatic 
stress [181]. 
In the longitudinal study we found that PLR led to a small, but insignificant increase in SV 
during 20+0 – 31+6 gestational weeks. Thereafter the SV actually decreased in response to PLR 
until term. We found significant decrease in CO from 24 weeks of gestation to term. The 
decrease in CO in response to PLR during the third trimester is in concordance with the 
observations made by Marques et al in a cross-sectional study at term [73]. Paradoxically, the 
PLR resulted in a reduction in cardiac contractility in the second half of pregnancy, and reduced 
cardiac contractility could be one possible explanation for the decreased preload reserve after 
32 gestational weeks. We observed an increase in SVR after 32 weeks in spite of reduced blood 
pressure, indicating reduced ability of the heart to increase CO towards the end of pregnancy. 
We compared preload functional hemodynamic response to PLR between pregnant women with 
normal and abnormal UtA PI. Functional hemodynamic variables did not differ significantly 
between groups. However, we found different trends in LCWI and VI in the response to PLR, 
indicating that women with abnormal UtA PI may be volume depleted compared to those with 
normal UtA PI. Pregnant women who subsequently develop early onset PE are known to have 
lower CO and higher SVR [48, 182]. We found that pregnant women with high UtA PI have 
significantly higher MAP and SVR, and lower SV and CO compared to women with normal 
UtA PI. There are only few published studies evaluating cardiovascular function during postural 
changes, and no other longitudinal studies assessing response to PLR during pregnancy to 
compare our results.  Further studies are needed to validate our findings. 
10.2 Cardiac contractility in pregnancy 
The PEP and LVET, STR, VI, ACI and LCWI provide information of ventricular systolic 
function. The trend of change in these variables indicates that the contractility of the left 
ventricle was not altered by PLR both in pregnant and non-pregnant women. Our results during 
the second half of pregnancy showed a reduction in ACI and VI, prolongation of PEP, and 
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shortening of LVET at baseline with advancing gestational age (Paper II). This may reflect 
decreased contractility of the left ventricle in the third trimester of pregnancy in accordance 
with other reports [34, 52]. 
Women with high UtA PI had lower values of ACI and VI compared to women with normal 
UtA PI. The physiological response to PLR was not significantly different between the groups 
with regards to the parameters of cardiac contractility and work, but the VI and LCWI changed 
in opposite directions; PLR led to a small increase in LCWI and VI in women with high UtAPI, 
and a decrease in the normal UtA PI group. Overall our results do not indicate that the pregnant 
women with high UtA PI have overt cardiac dysfunction. However, larger studies are needed 
to confirm our findings. 
10.3 Static measures of maternal systemic hemodynamics 
The CO was significantly higher among pregnant women at 22-24 weeks compared to non-
pregnant women (Paper I), which is in accordance with the study by Droste et al [28]. Tables 
1-3 gives an overview of previously published studies performed using different methods 
showing differences in the absolute values of CO and SV reported previously. CO has been 
shown to increase from early pregnancy plateauing at mid- gestation and then decreasing 
toward term, or increasing throughout pregnancy [22]. A recent meta-analyses of 39 studies 
concluded that CO increases during pregnancy peaking in the early third trimester [183]. 
Invasive methods such as dye dilution [17] appear to show higher CO in left-lateral position 
compared to supine. Echocardiographic studies performed in left-lateral position (Table 2) 
show an increase of CO from 5.24 L/min at 5 weeks [29] to 8.5 L/min at term [31]. Only nine 
longitudinal studies applying ICG method to investigate maternal hemodynamics have been 
published previously, which report variable findings (CO is stable, increases or decreases with 
advancing gestational age). In our longitudinal study, we found that the CO increased from 6.58 
L/min to 7.11 L/min from 20 weeks of gestation to term (Paper II). 
 
10.4 Functional hemodynamics in pregnancy 
Maternal position may affect hemodynamics especially in late pregnancy. However, few studies 
have investigated cardiovascular response to postural changes in pregnancy and the reports vary 
in their findings. Some studies report higher values of SV and CO in left lateral compared to 
supine or standing position [22, 24], whilst others found no difference between supine and left 
lateral position at 36-39 weeks [7]. The adaptive cardiovascular response to active postural 
changes in pregnancy is complex and affected by the activity as well as mechanical (e.g. 
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pressure of gravid uterus on the inferior vena cava), gravitational (e.g. pooling of blood in the 
lower body in a standing position) and autonomic (e.g. baroreflex response to decreased aortic 
pressure on standing from a supine position) factors. These have to be taken into account when 
interpreting the findings of functional hemodynamic investigations during pregnancy based on 
position changes. PLR causes an increase in venous return to the heart without changing other 
physiological variables and allows evaluating cardiovascular response to an increase in preload. 
However, the amount of autotransfusion effected by PLR can not be readily assessed and 
individual responses may vary. 
10.5 Validity of the studies 
All examinations were performed in a standardized manner with the women in a supine semi-
recumbent position to avoid compression of the inferior vena cava by the gravid uterus. 
Regarding the validity of methods used to investigate hemodynamics, use of noninvasive 
methods, such as ICG and Doppler ultrasonography, is important in studies on pregnant women 
where repeated measurements are necessary. 
ICG is a risk free, noninvasive method that provides continuous assessment of multiple 
parameters of the cardiovascular function in a single session. The method has been used for the 
last 50 years [154]. Several studies have investigated the validity of ICG in clinical and research 
settings. Although some concerns have been expressed regarding the validity using ICG in 
pregnancy [66], recent studies have demonstrated its accuracy, reliability and repeatability to 
be good [7, 51, 155, 184]. Masaki et al and Clark et al have reported an excellent correlation 
(0.91 and 0.915), respectively between CO measured by ICG and thermodilution in complicated 
and healthy pregnancies, respectively [86, 185]. Other validation studies between ICG and 
invasive methods have been performed using band electrodes instead of the currently used spot 
electrodes, but report good correlation between measured parameters in healthy pregnancies 
[91, 186]. 
Several studies have used the ICG monitor, BioZ, with refined technology and compared with 
echocardiography in pre-eclamptic women and healthy pregnant women during the third 
trimester and report good agreement and correlation between methods [51] [187]. The ICG has 
been shown to be reliable in identifying women with severe forms of PE, stratifying pregnant 
women with various forms of hypertensive disorders [188]. Villacorte et al investigated 31 
patients (58% men) using ICG and CMRI and found a good agreement between methods for 
determining CO (r=0.79) and SV (r=0.88) [189]. 
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Tomsin et al report a good correlation (r≥0.80) comparing cardiac contractility parameters and 
TFC by position change in healthy and pre-eclamptic women using the third generation device 
[184]. Burlingame et al showed that ICG has the ability to detect small changes in maternal SV 
associated with change of position from left lateral to supine semi-recumbent [51], whereas 
echocardiography lacked the sensitivity to detect small changes in EF as the latter method 
cannot assess hemodynamics continuously. 
Although ICG is a relatively operator independent it requires attention to the details of the 
technique to obtain accurate hemodynamic measurements. These include correct positioning of 
the ICG electrodes to obtain correct signals [185]. The participant should not move during 
measurements, as an uncontrolled motion during examination may influence the results. 
Additionally, some conditions, such as heart disease with pulmonary edema, morbid obesity 
etc., may cause changes in baseline thoracic impedance. However, none of the participating 
women in our studies had such conditions. The ICG technology is user friendly, with a portable 
device, which is simple to use both in clinical and research settings. The use of ICG does not 
require special skills, as compared to Doppler echocardiography. Additionally, with ICG it is 
possible to obtain continuous measurements of cardiovascular variables, which makes it 
suitable for detecting trends over time. 
All ICG examinations were performed by a single operator (ÅV) and in the same room with 
stable temperature using the same electronically steerable bed and the same ICG device. The 
participants were told not to speak or move during the examinations. We performed a 
repeatability study in 20 pregnant women at different gestational ages showing good 
reproducibility of SV, HR, CO and SVR measured by ICG. 
Doppler ultrasonography of the UtA is a widely used method in clinical practice and has been 
shown to have a reasonable good reproducibility [190]. All the doctors who performed 
examinations were appropriately trained and had several years of experience in this 
methodology. 
Regarding internal validity, it could be argued that the recruitment of non-pregnant women (in 
study I) from among the hospital and university staff might have caused some selection bias. 
However, as all pregnant women residing in the area attend the same hospital for the second 
trimester routine ultrasound examination the pregnant population should be representative of 
the source population. 
Regarding external validity, our study population had a fairly homogeneous ethnic and 
socioeconomic background and we believe that our sample population is representative of the 
White European population. However, our findings, especially the reference ranges for the 
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static and functional parameters of cardiovascular function may not be generalizable to other 
multiethnic populations. 
10.6 Limitations of the study 
There are some limitations of our study. We did not examine the participants before pregnancy, 
in the first trimester or postpartum to evaluate changes from the pre-pregnancy state until after 
delivery. In Norway first trimester ultrasound is not offered as a routine investigation, therefore 
recruitment of the women to the study in early pregnancy is difficult. Additionally, we did not 
obtain blood samples from all the participants to evaluate possible relevant biochemical markers 
of cardiovascular function, which might have added more information to our study. 
 
11 CONCLUSIONS 
We studied functional hemodynamics in healthy pregnant women and women at increased risk 
of developing placental dysfunction disorders. Maternal hemodynamics was found to be 
different in healthy pregnant women compared to non-pregnant women. In healthy pregnancies, 
the physiological response to PLR was not modified at 22-24 weeks of gestation. 
Longitudinal reference ranges for maternal functional hemodynamics were established for the 
second half of pregnancy. Healthy pregnant women appear to have limited preload reserve, 
especially in the third trimester, and might be vulnerable to fluid overload and cardiac failure. 
The functional hemodynamic profile of pregnant women with high UtA PI at 22-24 weeks was 
similar to that of controls, suggesting that its assessment is unlikely to improve the value of 
UtA Doppler in predicting pregnancy complications. 
 
12 FUTURE PERSPECTIVES 
Future studies on maternal hemodynamics and cardiac function aiming at prediction of 
pregnancy complications could include measurement of biomarkers sensitive in identifying 
subtle cardiovascular dysfunction. Investigations of pregnant women during the first trimester 
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Table 5. Longitudinal reference ranges of preload reserve for maternal stroke volume (ml) 
during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 
 
90th 95th 97.5th 
20 -19.9 -16.3 -12.2 2.3 16.7 20.8 24.4 
21 -20.2 -16.6 -12.5 2.0 16.4 20.6 24.1 
22 -20.4 -16.9 -12.8 1.7 16.2 20.3 23.8 
23 -20.7 -17.1 -13.0 1.5 15.9 20.0 23.6 
24 -20.9 -17.4 -13.2 1.2 15.7 19.8 23.4 
25 -21.1 -17.6 -13.5 1.0 15.5 19.6 23.2 
26 -21.3 -17.8 -13.6 0.8 15.3 19.4 23.0 
27 -21.5 -17.9 -13.8 0.7 15.1 19.2 22.8 
28 -21.7 -18.1 -14.0 0.5 15.0 19.1 22.6 
29 -21.8 -18.2 -14.1 0.3 14.8 18.9 22.5 
30 -22.0 -18.4 -14.3 0.2 14.7 18.8 22.3 
31 -22.1 -18.5 -14.4 0.1 14.5 18.6 22.2 
32 -22.2 -18.7 -14.5 -0.1 14.4 18.5 22.1 
33 -22.3 -18.8 -14.7 -0.2 14.3 18.4 22.0 
34 -22.4 -18.9 -14.8 -0.3 14.2 18.3 21.8 
35 -22.5 -19.0 -14.9 -0.4 14.1 18.2 21.7 
36 -22.6 -19.1 -15.0 -0.5 14.0 18.1 21.6 
37 -22.7 -19.2 -15.1 -0.6 13.9 18.0 21.5 
38 -22.8 -19.3 -15.2 -0.7 13.8 17.9 21.5 
39 -22.9 -19.4 -15.2 -0.8 13.7 17.8 21.4 
40 -23.0 -19.4 -15.3 -0.8 13.6 17.7 21.3 
 
Table 6. Longitudinal reference ranges of preload reserve for maternal heart rate (/min) during 
second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -17.7 -15.2 -12.4 -2.5 7.5 10.3 12.7 
21 -17.7 -15.3 -12.4 -2.5 7.4 10.3 12.7 
22 -17.8 -15.3 -12.5 -2.6 7.4 10.2 12.6 
23 -17.8 -15.4 -12.6 -2.6 7.3 10.1 12.6 
24 -17.9 -15.4 -12.6 -2.7 7.3 10.1 12.5 
25 -18.0 -15.5 -12.7 -2.8 7.2 10.0 12.4 
26 -18.0 -15.6 -12.8 -2.8 7.1 9.9 12.4 
27 -18.1 -15.7 -12.9 -2.9 7.0 9.8 12.3 
28 -18.2 -15.8 -12.9 -3.0 6.9 9.7 12.2 
29 -18.3 -15.9 -13.0 -3.1 6.8 9.7 12.1 
30 -18.4 -16.0 -13.1 -3.2 6.7 9.5 12.0 
31 -18.5 -16.1 -13.3 -3.3 6.6 9.4 11.9 
32 -18.6 -16.2 -13.4 -3.4 6.5 9.3 11.8 
33 -18.8 -16.3 -13.5 -3.6 6.4 9.2 11.6 
34 -18.9 -16.5 -13.6 -3.7 6.2 9.1 11.5 
35 -19.0 -16.6 -13.8 -3.8 6.1 8.9 11.4 
36 -19.2 -16.7 -13.9 -4.0 6.0 8.8 11.2 
37 -19.3 -16.9 -14.1 -4.1 5.8 8.6 11.1 
38 -19.5 -17.1 -14.3 -4.3 5.6 8.4 10.9 
39 -19.7 -17.2 -14.4 -4.5 5.4 8.3 10.7 
40 -19.9 -17.4 -14.6 -4.7 5.3 8.1 10.5 
 
Table 7. Longitudinal reference ranges of preload reserve for maternal cardiac output (L/min) 
during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -18.3 -15.3 -11.8 1.0 14.1 17.9 21.3 
21 -18.9 -15.9 -12.4 0.3 13.5 17.3 20.6 
22 -19.4 -16.4 -12.9 -0.2 12.9 16.7 20.0 
23 -19.9 -16.9 -13.4 -0.7 12.4 16.2 19.5 
24 -20.3 -17.3 -13.9 -1.2 11.9 15.7 19.0 
25 -20.7 -17.8 -14.3 -1.6 11.5 15.3 18.6 
26 -21.1 -18.1 -14.6 -2.0 11.1 14.9 18.2 
27 -21.4 -18.5 -15.0 -2.4 10.7 14.5 17.8 
28 -21.7 -18.8 -15.3 -2.7 10.4 14.1 17.4 
29 -22.0 -19.1 -15.6 -3.0 10.0 13.8 17.1 
30 -22.3 -19.4 -15.9 -3.3 9.7 13.5 16.8 
31 -22.6 -19.6 -16.2 -3.6 9.4 13.2 16.5 
32 -22.8 -19.9 -16.4 -3.9 9.2 12.9 16.2 
33 -23.0 -20.1 -16.6 -4.1 8.9 12.7 16.0 
34 -23.2 -20.3 -16.9 -4.3 8.7 12.5 15.7 
35 -23.4 -20.5 -17.1 -4.5 8.5 12.2 15.5 
36 -23.6 -20.7 -17.3 -4.7 8.3 12.0 15.3 
37 -23.8 -20.9 -17.4 -4.9 8.1 11.8 15.1 
38 -24.0 -21.0 -17.6 -5.1 7.9 11.6 14.9 
39 -24.1 -21.2 -17.8 -5.3 7.7 11.5 14.7 
40 -24.3 -21.4 -17.9 -5.4 7.5 11.3 14.6 
 
Table 8. Longitudinal reference ranges of preload reserve for maternal mean arterial pressure 
(mmHg) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -14.7 -13.1 -11.3 -5.6 -0.5 0.9 2.1 
21 -14.3 -12.7 -11.0 -5.3 -0.2 1.1 2.3 
22 -14.0 -12.5 -10.7 -5.1 -0.0 1.3 2.5 
23 -13.8 -12.2 -10.5 -4.9 0.2 1.5 2.7 
24 -13.6 -12.0 -10.3 -4.7 0.3 1.7 2.9 
25 -13.4 -11.9 -10.1 -4.6 0.5 1.9 3.0 
26 -13.3 -11.7 -10.0 -4.4 0.6 2.0 3.1 
27 -13.2 -11.6 -9.9 -4.3 0.8 2.1 3.3 
28 -13.1 -11.5 -9.8 -4.2 0.9 2.2 3.4 
29 -13.0 -11.4 -9.7 -4.1 1.0 2.3 3.5 
30 -12.9 -11.3 -9.6 -4.0 1.1 2.4 3.6 
31 -12.8 -11.3 -9.5 -3.9 1.2 2.5 3.7 
32 -12.8 -11.2 -9.5 -3.9 1.2 2.6 3.8 
33 -12.7 -11.2 -9.4 -3.8 1.3 2.7 3.9 
34 -12.7 -11.1 -9.4 -3.7 1.4 2.8 3.9 
35 -12.6 -11.1 -9.3 -3.7 1.4 2.8 4.0 
36 -12.6 -11.0 -9.3 -3.6 1.5 2.9 4.1 
37 -12.6 -11.0 -9.2 -3.6 1.6 2.9 4.1 
38 -12.5 -11.0 -9.2 -3.5 1.6 3.0 4.2 
39 -12.5 -10.9 -9.2 -3.5 1.6 3.0 4.2 
40 -12.5 -10.9 -9.2 -3.5 1.7 3.1 4.3 
 
Table 9. Longitudinal reference ranges of preload reserve for maternal mean systemic vascular 
resistance (dyne s/cm5) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -23.9 -21.7 -18.9 -7.3 6.4 10.6 14.4 
21 -22.7 -20.4 -17.6 -6.2 7.1 11.2 14.9 
22 -21.7 -19.4 -16.6 -5.3 7.9 12.0 15.5 
23 -21.0 -18.7 -15.8 -4.4 8.7 12.8 16.4 
24 -20.4 -18.1 -15.2 -3.7 9.6 13.6 17.2 
25 -20.0 -17.7 -14.7 -3.0 10.4 14.5 18.2 
26 -19.8 -17.3 -14.3 -2.5 11.2 15.4 19.1 
27 -19.5 -17.1 -14.0 -1.9 12.0 16.3 20.0 
28 -19.4 -16.9 -13.8 -1.5 12.7 17.1 20.9 
29 -19.3 -16.7 -13.6 -1.0 13.4 17.8 21.8 
30 -19.2 -16.6 -13.4 -0.6 14.1 18.6 22.6 
31 -19.2 -16.5 -13.3 -0.3 14.7 19.3 23.3 
32 -19.2 -16.5 -13.2 0.0 15.3 19.9 24.1 
33 -19.1 -16.4 -13.1 0.3 15.8 20.5 24.8 
34 -19.1 -16.4 -13.0 0.6 16.3 21.1 25.4 
35 -19.1 -16.4 -12.9 0.8 16.8 21.7 26.0 
36 -19.2 -16.3 -12.9 1.1 17.2 22.2 26.6 
37 -19.2 -16.3 -12.8 1.3 17.6 22.6 27.1 
38 -19.2 -16.3 -12.8 1.5 18.0 23.1 27.6 
39 -19.2 -16.3 -12.7 1.6 18.4 23.5 28.0 
40 -19.2 -16.3 -12.7 1.8 18.7 23.9 28.5 
 
Table 10. Longitudinal reference ranges of preload reserve for maternal thoracic fluid content 
(1/kOhm) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -9 -7 -5 4 15 19 22 
21 -9 -7 -5 4 15 18 22 
22 -9 -7 -5 4 15 18 21 
23 -9 -7 -5 4 15 18 21 
24 -9 -8 -5 4 15 18 21 
25 -9 -8 -5 4 14 18 21 
26 -10 -8 -5 4 14 18 21 
27 -10 -8 -6 3 14 18 21 
28 -10 -8 -6 3 14 18 21 
29 -10 -8 -6 3 14 17 20 
30 -10 -8 -6 3 14 17 20 
31 -10 -8 -6 3 14 17 20 
32 -10 -8 -6 3 14 17 20 
33 -10 -8 -6 3 14 17 20 
34 -10 -8 -6 3 13 17 20 
35 -10 -8 -6 3 13 17 20 
36 -10 -8 -6 3 13 17 20 
37 -10 -8 -6 3 13 16 19 
38 -10 -9 -6 2 13 16 19 
39 -10 -9 -6 2 13 16 19 
40 -10 -9 -7 2 13 16 19 
 
Table 11. Longitudinal reference ranges of preload reserve for maternal acceleration index 
(1/100 s2) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -37 -33 -27 -2 31 42 51 
21 -38 -33 -27 -2 30 41 50 
22 -38 -34 -28 -3 29 40 49 
23 -39 -34 -28 -4 29 39 49 
24 -39 -34 -29 -4 28 38 48 
25 -39 -35 -29 -5 27 38 47 
26 -40 -35 -30 -5 27 37 46 
27 -40 -35 -30 -6 26 36 46 
28 -40 -36 -30 -6 25 36 45 
29 -40 -36 -31 -7 25 35 44 
30 -41 -36 -31 -7 24 34 44 
31 -41 -37 -31 -7 24 34 43 
32 -41 -37 -31 -8 23 33 43 
33 -41 -37 -32 -8 23 33 42 
34 -41 -37 -32 -8 22 33 42 
35 -42 -37 -32 -9 22 32 41 
36 -42 -38 -32 -9 22 32 41 
37 -42 -38 -33 -9 21 31 41 
38 -42 -38 -33 -10 21 31 40 
39 -42 -38 -33 -10 21 31 40 
40 -42 -38 -33 -10 20 30 39 
 
Table 12. Longitudinal reference ranges of preload reserve for maternal velocity index 
(1/1000s) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -34 -30 -26 -7 15 21 27 
21 -34 -30 -26 -7 15 21 27 
22 -34 -31 -26 -7 15 21 27 
23 -35 -31 -26 -7 15 21 27 
24 -35 -31 -26 -7 15 21 27 
25 -35 -31 -26 -7 15 21 27 
26 -35 -31 -26 -7 15 21 27 
27 -35 -31 -26 -7 15 21 27 
28 -35 -31 -26 -7 15 21 27 
29 -35 -31 -26 -7 15 21 27 
30 -35 -31 -26 -7 15 21 27 
31 -35 -31 -26 -7 15 22 27 
32 -35 -31 -26 -7 15 22 28 
33 -35 -31 -27 -7 15 22 28 
34 -36 -32 -27 -7 15 22 28 
35 -36 -32 -27 -7 15 22 28 
36 -36 -32 -27 -7 15 22 28 
37 -37 -32 -27 -7 15 22 29 
38 -37 -33 -28 -8 16 23 29 
39 -37 -33 -28 -8 16 23 29 
40 -38 -33 -28 -8 16 23 30 
 
Table 13. Longitudinal reference ranges of preload reserve for maternal pre-ejection period 
(ms) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -43 -39 -34 -14 9 17 24 
21 -41 -37 -33 -13 11 19 26 
22 -40 -36 -31 -11 13 21 28 
23 -39 -35 -30 -9 16 23 30 
24 -38 -33 -28 -7 18 25 32 
25 -36 -32 -27 -6 20 27 35 
26 -35 -31 -26 -4 21 29 37 
27 -34 -30 -24 -3 23 31 38 
28 -33 -29 -23 -1 25 33 40 
29 -32 -28 -22 -0 26 34 41 
30 -32 -27 -22 1 27 35 43 
31 -31 -27 -21 1 28 36 43 
32 -31 -26 -21 2 28 36 44 
33 -31 -26 -21 2 28 37 44 
34 -31 -27 -21 1 28 36 44 
35 -32 -27 -21 1 27 36 43 
36 -32 -28 -22 -0 26 34 42 
37 -33 -29 -23 -2 24 33 40 
38 -35 -30 -25 -3 22 30 38 
39 -36 -32 -27 -6 20 28 35 
40 -38 -34 -29 -8 16 24 31 
 
Table 14. Longitudinal reference ranges of preload reserve for maternal left ventricular ejection 
time (ms) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -21.9 -17.9 -13.1 5.1 25.2 31.2 36.4 
21 -21.8 -17.8 -13.1 5.0 24.8 30.7 35.9 
22 -21.7 -17.8 -13.1 4.9 24.5 30.3 35.4 
23 -21.6 -17.7 -13.1 4.7 24.2 29.9 35.0 
24 -21.6 -17.7 -13.1 4.6 23.9 29.6 34.7 
25 -21.6 -17.7 -13.1 4.4 23.6 29.3 34.3 
26 -21.6 -17.8 -13.2 4.3 23.4 29.1 34.1 
27 -21.6 -17.9 -13.3 4.1 23.2 28.8 33.8 
28 -21.7 -18.0 -13.4 4.0 23.0 28.7 33.6 
29 -21.9 -18.1 -13.5 3.8 22.9 28.5 33.5 
30 -22.0 -18.2 -13.7 3.7 22.8 28.4 33.4 
31 -22.2 -18.4 -13.9 3.6 22.7 28.3 33.3 
32 -22.4 -18.7 -14.1 3.4 22.6 28.3 33.3 
33 -22.7 -18.9 -14.3 3.3 22.6 28.3 33.3 
34 -23.0 -19.2 -14.6 3.1 22.6 28.3 33.4 
35 -23.3 -19.5 -14.8 3.0 22.6 28.4 33.5 
36 -23.6 -19.8 -15.1 2.8 22.6 28.5 33.7 
37 -24.0 -20.1 -15.4 2.7 22.7 28.6 33.9 
38 -24.4 -20.5 -15.8 2.6 22.8 28.8 34.1 
39 -24.8 -20.9 -16.1 2.4 22.9 29.0 34.4 
40 -25.3 -21.3 -16.5 2.3 23.0 29.2 34.7 
 
Table 15. Longitudinal reference ranges of preload reserve for maternal systolic time ratio (%) 
during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -51 -47 -42 -19 13 24 35 
21 -50 -46 -41 -17 16 27 38 
22 -49 -45 -39 -15 19 30 41 
23 -48 -43 -38 -13 21 33 44 
24 -47 -42 -37 -11 24 36 47 
25 -46 -41 -35 -9 26 38 50 
26 -45 -40 -34 -8 29 41 53 
27 -44 -39 -33 -6 31 43 55 
28 -43 -38 -32 -5 33 45 57 
29 -42 -37 -31 -3 34 47 59 
30 -41 -37 -30 -2 36 49 61 
31 -41 -36 -30 -2 37 50 62 
32 -41 -36 -29 -1 38 51 63 
33 -41 -36 -29 -1 38 51 63 
34 -41 -36 -30 -1 37 50 62 
35 -41 -36 -30 -2 36 49 61 
36 -42 -37 -31 -3 35 48 60 
37 -43 -38 -32 -5 33 45 57 
38 -44 -39 -33 -7 30 42 54 
39 -46 -41 -35 -9 26 39 50 
40 -47 -43 -37 -12 22 34 45 
 
Table 16. Longitudinal reference ranges of preload reserve for maternal left ventricular work 
index (Kg m/m2) during second half of pregnancy. 
    Percentile    
Gestation 
(weeks) 
2.5th 5th 10th 50th 90th 95th 97.5th 
20 -26.4 -23.2 -19.4 -5.9 8.2 12.2 15.7 
21 -26.5 -23.3 -19.5 -6.0 7.9 11.9 15.4 
22 -26.5 -23.4 -19.7 -6.2 7.7 11.7 15.2 
23 -26.7 -23.5 -19.8 -6.4 7.4 11.4 14.9 
24 -26.8 -23.7 -20.0 -6.6 7.3 11.2 14.7 
25 -27.0 -23.8 -20.1 -6.7 7.1 11.1 14.5 
26 -27.2 -24.1 -20.3 -6.9 6.9 10.9 14.4 
27 -27.5 -24.3 -20.6 -7.1 6.8 10.8 14.3 
28 -27.8 -24.6 -20.8 -7.3 6.7 10.8 14.3 
29 -28.1 -24.9 -21.1 -7.5 6.7 10.7 14.3 
30 -28.5 -25.2 -21.4 -7.6 6.6 10.7 14.3 
31 -28.8 -25.6 -21.7 -7.8 6.6 10.7 14.4 
32 -29.3 -25.9 -22.1 -8.0 6.6 10.8 14.5 
33 -29.7 -26.4 -22.4 -8.2 6.6 10.9 14.6 
34 -30.2 -26.8 -22.8 -8.3 6.6 11.0 14.7 
35 -30.7 -27.2 -23.2 -8.5 6.7 11.1 14.9 
36 -31.2 -27.7 -23.6 -8.7 6.8 11.2 15.1 
37 -31.7 -28.2 -24.0 -8.9 6.9 11.4 15.4 
38 -32.3 -28.7 -24.5 -9.1 7.0 11.6 15.7 
39 -32.9 -29.2 -24.9 -9.2 7.1 11.8 16.0 
40 -33.5 -29.8 -25.4 -9.4 7.2 12.1 16.3 
 
